UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
____________________
FORM 10-Q
____________________
(Mark One)
| | | | | |
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2023March 31, 2024
OR
| | | | | |
| o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from ______ to ______
Commission File Number: 001-38205
____________________
ZAI LAB LIMITED
(Exact Name of Registrant as Specified in its Charter)
____________________
| | | | | |
| Cayman Islands | 98-1144595 |
(State or Other Jurisdiction of
Incorporation or Organization) | (I.R.S. Employer
Identification No.) |
| |
4560 Jinke Road Bldg. 1, Fourth Floor, Pudong Shanghai China | 201210 |
314 Main Street
4th Floor, Suite 100
Cambridge, MA, USA | 02142 |
| (Address of Principal Executive Offices) | (Zip Code) |
| |
+86 216163 2588
+1 857 706 2604
(Registrant’s Telephone Number, Including Area Code)
____________________
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
| American Depositary Shares, each representing 10 Ordinary Shares, par value $0.000006 per share | | ZLAB | | The Nasdaq Global Market |
| Ordinary Shares, par value $0.000006 per share* | | 9688 | | The Stock Exchange of Hong Kong Limited |
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | | | | |
| Large accelerated filer | x | | Accelerated filer | o |
| Non-accelerated filer | o | | Smaller reporting company | o |
| Emerging growth company | o | | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of August 1, 2023, 983,887,430May 2, 2024, 992,087,430 ordinary shares of the registrant, par value $0.000006 per share, were outstanding, of which 749,901,320758,101,320 ordinary shares were held in the form of American Depositary Shares.
Zai Lab Limited
Quarterly Report on Form 10-Q
For the SecondFirst Quarter of 20232024
SPECIAL NOTES REGARDING THE COMPANY
Forward-Looking Statements
This report contains certain forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; the market for our commercial and pipeline products; capital allocation and investment strategy; clinical development programs and related clinical trials; clinical trial data, data readouts, and presentations; risks and uncertainties associated with drug development and commercialization; regulatory discussions, submissions, filings, and approvals and the timing thereof; the potential benefits, safety, and efficacy of our products and product candidates and those of our collaboration partners; the anticipated benefits and potential of investments, collaborations, and business development activities; our profitability and timeline to profitability; and our future financial and operating results. All statements, other than statements of historical fact, included in this report are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this report and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to the following:
• Our ability to successfully commercialize and generate revenue from our approved products;
• Our ability to obtain funding for our operations and business initiatives;
• The results of our clinical and pre-clinical development of our product candidates;
• The content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates;
• Changes in United StatesU.S. and China trade policies and relations, as well as relations with other countries, and/or changes in regulations and/or sanctions;
• Actions the Chinese government may take to intervene in or influence our operations;
• Economic, political, and social conditions in mainland China, as well as governmental policies;
• Uncertainties in the Chinese legal system, including with respect to the anti-corruption enforcement efforts in China and the Counter-Espionage Law, the Data Security Law, the Cyber Security Law, the Cybersecurity Review Measures, the Personal Information Protection Law, the Regulation on the Administration of Human Genetic Resources, the Biosecurity Law, the Measures on Security Assessment of Cross-Border Data Transfer (the “Security Assessment Measures”), and other future laws and regulations or amendments to such laws and regulations;
• The effects of the COVID-19 pandemic, particularly in mainland China where our operations and product markets are primarily located;
• Approval, filing, or procedural requirements imposed by the China Securities Regulatory Commission (“CSRC”) or other Chinese regulatory authorities in connection with issuing securities to foreign investors under Chinese law;
• Any violation or liability under the U.S. Foreign Corrupt Practices Act (“FCPA”) or Chinese anti-corruption laws;
• Restrictions on currency exchange;
• Limitations on the ability of our Chinese subsidiaries to make payments to us;
• Chinese requirements on the ability of residents in mainland China to establish offshore special purpose companies;
• Chinese regulations regarding acquisitions of companies based in mainland China by foreign investors;
• Any issues that our Chinese manufacturing facilities may have with operating in conformity with established Good Manufacturing Practices (“GMPs”) and international best practices, and with passing U.S. Food and Drug Administration (“FDA”), China National Medical Products Administration (“NMPA”), and European Medicines Agency (“EMA”) inspections;
• Expiration of, or changes to, financial incentives or discretionary policies granted by local governments in mainland China;
• Restrictions or limitations on the ability of overseas regulators to conduct investigations or collect evidence within mainland China;
• Business disruptions caused by pandemics such as COVID-19, international war or conflict such as the Russia/Ukraine and Israel/Hamas wars, natural disasters, extreme weather events, and other significant disruptions outside of our control;
• Unfavorable tax consequences to us and our non-Chinese shareholders or ADSAmerican Depositary Share (“ADS”) holders if we were to be classified as a Chinese resident enterprise for Chinese income tax purposes;
• Failure to comply with applicable Chinese, U.S., and Hong Kong regulations that could lead to government enforcement actions, fines, other legal or administrative sanctions, and/or harm to our business or reputation;
• Review by the U.S. Committee on Foreign Investment (“CFIUS”) in our investments or other delays or obstacles for closing transactions;
• Any inability to renew our current leases on desirable terms or otherwise locate desirable alternatives for our leased properties;
• Our ability to generate revenues from our approved commercial products;
• Any inability of third parties on whom we rely to conduct our pre-clinical and clinical trials to successfully carry out their contractual duties or meet expected deadlines; and
• Any inability to obtain or maintain sufficient patent protection for our products and product candidates.
These factors should not be construed as exhaustive and should be read with the other cautionary statements and information in our Annual Report on Form 10-K for the year ended December 31, 2022 (the “2022 Annual Report”), Quarterly Report on Form 10-Q for the three months ended March 31, 2023 (the “Q1 2023 Form 10-Q”“2023 Annual Report”), and this report. Forward-looking statements are based on our management’s beliefs and assumptions and information currently available to our management. These statements, like all statements in this report, speak only as of their date. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this report.
Usage of Terms
Unless the context requires otherwise, references in this report to “Greater China” refer to mainland China, Hong Kong Special Administrative Region (“Hong Kong” or “HK”), Macau Special Administrative Region (“Macau”), and Taiwan, collectively; references to “Zai Lab,” the “Company,” “we,” “us,” and “our” refer to Zai Lab Limited, a holding company, and its subsidiaries, on a consolidated basis; and references to “Zai Lab Limited” refer to Zai Lab Limited, a holding company. Zai Lab Limited is the entity in which investors hold their interest.
Our operating subsidiaries consist of Zai Lab (Hong Kong) Limited, domiciled in Hong Kong; Zai Auto Immune (Hong Kong) Limited, domiciled in Hong Kong; Zai Anti Infectives (Hong Kong) Limited, domiciled in Hong Kong; Zai Lab (Shanghai) Co., Ltd., domiciled in mainland China; Zai Lab International Trading (Shanghai) Co., Ltd., domiciled in mainland China; Zai Lab (Suzhou) Co., Ltd., domiciled in mainland China; Zai Biopharmaceutical (Suzhou) Co., Ltd., domiciled in mainland China; Zai Lab Trading (Suzhou) Co., Ltd., domiciled in mainland China; Zai Lab (Taiwan) Limited, domiciled in Taiwan; Zai Lab (AUST) Pty. Ltd., domiciled in Australia; and Zai Lab (US) LLC, domiciled in the United States. As of the date of this report, Zai Anti Infectives (Hong Kong) Limited has non-substantial business operations.
We own various registered trademarks, trademark applications, and unregistered trademarks and service marks, including various forms of the “ZAI LAB”Zai Lab brand (in English and “再鼎医药” brands,Chinese), as well as several domain names incorporating some or all of these trademarksthat incorporate such trademarks. Trademarks and our corporate logo. All other trade names trademarks, and service marks of other companies appearing in this report are the property of their respective holders. Solely for convenience, some of the trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of, any other company.
Disclosures Relating to Our Chinese Operations
Zai Lab Limited is an exempted company incorporated in the Cayman Islands on March 28, 2013 with limited liability. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. We have substantial operations in mainland China. Below is a summary of certain risks related to our Chinese operations. For more information on these risks and other risks relating to our ADSs and ordinary shares (considered individually or together, “our securities”) and for material regulations that may affect our business and an investment in our securities, see Item 1A. Risk Factors and Item 1. Business – Government Regulation in our 2022 Annual Report.
Zai Lab Limited is not a Chinese operating company, but a holding company incorporated in the Cayman Islands.
Zai Lab Limited is not a Chinese operating company, but a holding company incorporated in the Cayman Islands. As a holding company, we conduct a substantial portion of our operations through wholly owned subsidiaries based in mainland China. Our investors do not hold direct investments in our Chinese operating companies. In July 2021, the Chinese government provided new guidance on Chinese companies raising capital outside of mainland China, including through arrangements called variable interest entities (“VIEs”). Currently, our corporate structure contains no VIEs, and the life sciences industry in which we operate is not subject to foreign ownership limitations in mainland China. However, there are uncertainties with respect to the Chinese legal system, and there may be changes in laws, regulations, and policies, including how those laws, regulations, and policies will be interpreted or implemented, that may affect our business or an investment in our business. If, in the future, the Chinese government determines that our corporate structure does not comply with Chinese regulations, or if Chinese regulations change or are interpreted differently, the value of our securities may decline or become worthless.
There are significant legal and operational risks associated with conducting a substantial portion of our operations in mainland China, including with respect to changes in the legal, political, and economic policies of the Chinese government, relations between mainland China and the United States, or Chinese or U.S. regulations, that may materially and adversely affect our business, financial condition, results of operations, ability to raise capital or continue to offer our securities, and the market price of our securities.
There are significant legal and operational risks associated with conducting a substantial portion of our operations in mainland China, including with respect to changes in the legal, political, and economic policies of the Chinese government, relations between mainland China and the United States, or Chinese or U.S. regulations. For example, geopolitical events, such as developments with respect to Taiwan, continue to cause heightened tensions between the United States and China. In addition, new laws and regulations, including the Counter-Espionage Law, Personal Information Protection Law, Data Security Law, Cyber Security Law and Cybersecurity Review Measures, Measures on Security Assessment of Cross-Border Data Transfer, and regulations and guidelines relating to the multi-level protection scheme, have imposed, and may continue to impose, additional restrictions or obligations and compliance-related costs on our business. In addition, our business, or our directors or employees, may be subject to enforcement actions or penalties if it is determined that we, or they, have not complied with applicable laws and regulations. Such legal and operational risks may materially and adversely affect our business, financial condition, results of operations, ability to raise capital or continue to offer our securities, and the market price of our securities.
We are or may be required to obtain certain permissions from Chinese authorities to operate in mainland China, issue our securities to foreign investors, and transfer certain scientific data.
The Chinese government has exercised, and may continue to exercise, substantial influence or control over virtually every sector of the Chinese economy through regulation and state ownership. As a result, we are or may be required to obtain certain approvals or permissions from Chinese authorities to operate in mainland China, transfer certain scientific data, and issue our securities to foreign investors.
For example, we are required to obtain certain approvals from Chinese authorities to operate our Chinese subsidiaries. To operate our general business activities in mainland China, each of our Chinese subsidiaries is required to obtain a business license from the local counterpart of the State Administration for Market Regulation (“SAMR”). Each of our Chinese subsidiaries has obtained such a business license. Our Chinese subsidiaries are also required to obtain certain licenses and permits, including but not limited to the following: Pharmaceutical Manufacturing Permits, Pharmaceutical Distribution Permits, and Medical Device Distribution Permits to manufacture and/or distribute drugs and/or applicable medical devices. No application for any such material license or permit has been denied.
Further, we are required to obtain certain approvals from Chinese authorities before transferring certain scientific data abroad or to foreign parties or entities established or controlled by those foreign parties. In addition, we may be subject to additional such requirements pursuant to the Security Assessment Measures, which may affect our Chinese subsidiaries or clinical trials. The Security Assessment Measures may require us to complete security assessments for certain cross-border data transfers, obtain prior approval from the Cyberspace Administration of China (“CAC”) for transfers out of mainland China of certain important or personal data, or obtain prior clearance or approval from the Human Genetic Resources Administration Office of China (“HGRAC”) for certain transfers of data derived from human organs, tissues, or cells of Chinese individuals that contain human genetic materials. If we are not able to obtain or maintain the necessary permissions or approvals, our ability to operate in mainland China may be restricted or prohibited, and the value of our securities could significantly decline or become worthless.
Although we are not currently required to obtain prior approval or permission from the CSRC or any other Chinese regulatory authority to issue our securities to foreign investors, the CSRC has promulgated a new set of regulations that consists of the Trial Administrative Measures for Overseas Securities Offering and Listing by Domestic Companies (the “Trial Measures”) and five supporting guidelines, which became effective in March 2023. Pursuant to the Trial Measures, we may be required to submit filings to the CSRC following the submission of future overseas listings and the completion of future offerings of our equity securities to foreign investors. If we are not able to complete the necessary filings for future securities offerings, our ability to raise capital may be adversely affected.
The central or local governments could impose new, stricter regulations or interpretations of existing regulations that could impose additional requirements, require additional approvals or permissions in the future, and result in additional related expenditures and efforts on our part to comply with such regulations or interpretations. Also, as there are uncertainties with respect to the Chinese legal system and changes in laws, regulations, and policies, including how those laws, regulations, and policies will be interpreted or implemented, our business and an investment in our securities could be adversely affected.
PART I – FINANCIAL INFORMATION
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the accompanying notes included in this report and the audited consolidated financial information and the accompanying notes included in our 20222023 Annual Report.
Item 1. Financial Statements.
Zai Lab Limited
Unaudited Condensed Consolidated Balance Sheets
(in thousands of U.S. dollars (“$”), except for number of shares and per share data)
| | | | | | | | | | | | | | | | | |
| Notes | | June 30,
2023 | | December 31,
2022 |
| | | | | |
| Assets | | | | | |
| Current assets: | | | | | |
| Cash and cash equivalents | 3 | | 859,155 | | | 1,008,470 | |
| Short-term investments | | | 15,500 | | | — | |
| Accounts receivable (net of allowance for credit loss of $14 and $11 as of June 30, 2023 and December 31, 2022, respectively) | | | 47,283 | | | 39,963 | |
| Notes receivable | | | 20,781 | | | 8,608 | |
| Inventories, net | 4 | | 36,353 | | | 31,621 | |
| Prepayments and other current assets | | | 38,433 | | | 35,674 | |
| Total current assets | | | 1,017,505 | | | 1,124,336 | |
| Restricted cash, non-current | | | 1,791 | | | 803 | |
| Long term investments | | | 5,128 | | | 6,431 | |
| Prepayments for equipment | | | 665 | | | 1,396 | |
| Property and equipment, net | 5 | | 56,410 | | | 57,863 | |
| Operating lease right-of-use assets | | | 18,537 | | | 19,512 | |
| Land use rights, net | | | 3,067 | | | 6,892 | |
| Intangible assets, net | | | 1,690 | | | 1,511 | |
| Long-term deposits | | | 1,580 | | | 1,396 | |
| | | | | |
| Total assets | | | 1,106,373 | | | 1,220,140 | |
| Liabilities and shareholders’ equity | | | | | |
| Current liabilities: | | | | | |
| Accounts payable | | | 67,031 | | | 65,974 | |
| Current operating lease liabilities | | | 7,299 | | | 7,050 | |
| Other current liabilities | 8 | | 59,024 | | | 66,818 | |
| Total current liabilities | | | 133,354 | | | 139,842 | |
| Deferred income | | | 28,625 | | | 21,360 | |
| Non-current operating lease liabilities | | | 11,755 | | | 13,343 | |
| Other non-current liabilities | | | 325 | | | — | |
| Total liabilities | | | 174,059 | | | 174,545 | |
| Commitments and contingencies (Note 15) | | | | | |
| Shareholders’ equity | | | | | |
| Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 973,355,390 and 962,455,850 shares issued as of June 30, 2023 and December 31, 2022, respectively; 968,566,280 and 960,219,570 shares outstanding as of June 30, 2023 and December 31, 2022, respectively) | | | 6 | | | 6 | |
| Additional paid-in capital | | | 2,932,053 | | | 2,893,120 | |
| Accumulated deficit | | | (2,031,399) | | | (1,861,360) | |
| Accumulated other comprehensive income | | | 52,180 | | | 25,685 | |
| Treasury Stock (at cost, 4,789,110 and 2,236,280 shares as of June 30, 2023 and December 31, 2022, respectively) | | | (20,526) | | | (11,856) | |
| Total shareholders’ equity | | | 932,314 | | | 1,045,595 | |
| Total liabilities and shareholders’ equity | | | 1,106,373 | | | 1,220,140 | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Zai Lab Limited
Unaudited Condensed Consolidated Statements of Operations
(in thousands of $, except for number of shares and per share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Three Months Ended June 30, | | Six Months Ended June 30, |
| Notes | | 2023 | | 2022 | | 2023 | | 2022 |
| | | | | | | | | |
| Revenues: | | | | | | | | | |
| Product revenue, net | 6 | | 68,864 | | | 47,575 | | | 131,661 | | | 93,670 | |
| Collaboration revenue | | | — | | | 601 | | | — | | | 1,230 | |
| Total revenues | | | 68,864 | | | 48,176 | | | 131,661 | | | 94,900 | |
| Expenses: | | | | | | | | | |
| Cost of sales | | | (23,763) | | | (17,407) | | | (45,100) | | | (33,051) | |
| Research and development | | | (76,682) | | | (66,084) | | | (125,153) | | | (119,938) | |
| Selling, general, and administrative | | | (67,920) | | | (63,401) | | | (130,430) | | | (120,392) | |
| Gain on sale of intellectual property | | | 10,000 | | | — | | | 10,000 | | | — | |
| Loss from operations | | | (89,501) | | | (98,716) | | | (159,022) | | | (178,481) | |
| Interest income | | | 10,090 | | | 1,175 | | | 20,321 | | | 1,363 | |
| Foreign currency loss | | | (40,079) | | | (34,895) | | | (31,167) | | | (32,610) | |
| Other expense, net | 13 | | (1,405) | | | (5,497) | | | (171) | | | (10,378) | |
| Loss before income tax and share of loss from equity method investment | | | (120,895) | | | (137,933) | | | (170,039) | | | (220,106) | |
| Income tax expense | 7 | | — | | | — | | | — | | | — | |
| Share of loss from equity method investment | | | — | | | — | | | — | | | (221) | |
| Net loss | | | (120,895) | | | (137,933) | | | (170,039) | | | (220,327) | |
| Net loss attributable to ordinary shareholders | | | (120,895) | | | (137,933) | | | (170,039) | | | (220,327) | |
| Loss per share - basic and diluted | 9 | | (0.13) | | | (0.14) | | | (0.18) | | | (0.23) | |
| Weighted-average shares used in calculating net loss per ordinary share - basic and diluted | | | 964,817,310 | | | 957,684,820 | | | 963,140,360 | | | 956,603,250 | |
| Loss per American Depositary Shares (“ADS”) - basic and diluted | | | (1.25) | | | (1.44) | | | (1.77) | | | (2.30) | |
| Weighted-average ADSs used in calculating net loss per ADS - basic and diluted | | | 96,481,731 | | | 95,768,482 | | | 96,314,036 | | | 95,660,325 | |
| | | | | | | | | | | | | | | | | |
| Notes | | March 31,
2024 | | December 31,
2023 |
| | | | | |
| Assets | | | | | |
| Current assets | | | | | |
| Cash and cash equivalents | 3 | | 650,780 | | | 790,151 | |
| Restricted cash, current | | | 100,000 | | | — | |
| Short-term investments | | | — | | | 16,300 | |
| Accounts receivable (net of allowance for credit losses of $18 and $17 as of March 31, 2024 and December 31, 2023, respectively) | | | 60,422 | | | 59,199 | |
| Notes receivable | | | 15,363 | | | 6,134 | |
| Inventories, net | 4 | | 37,851 | | | 44,827 | |
| Prepayments and other current assets | | | 24,224 | | | 22,995 | |
| Total current assets | | | 888,640 | | | 939,606 | |
| Restricted cash, non-current | | | 1,114 | | | 1,113 | |
| Long term investments | | | 14,109 | | | 9,220 | |
| Prepayments for equipment | | | 89 | | | 111 | |
| Property and equipment, net | 5 | | 52,386 | | | 53,734 | |
| Operating lease right-of-use assets | | | 15,187 | | | 14,844 | |
| Land use rights, net | | | 3,034 | | | 3,069 | |
| Intangible assets, net | | | 12,398 | | | 13,389 | |
| Long-term deposits | | | 1,480 | | | 1,209 | |
| | | | | |
| Total assets | | | 988,437 | | | 1,036,295 | |
| Liabilities and shareholders’ equity | | | | | |
| Current liabilities | | | | | |
| Accounts payable | | | 88,121 | | | 112,991 | |
| Current operating lease liabilities | | | 7,536 | | | 7,104 | |
| Short-term debts | 9 | | 48,273 | | | — | |
| Other current liabilities | 10 | | 48,176 | | | 82,972 | |
| Total current liabilities | | | 192,106 | | | 203,067 | |
| Deferred income | | | 26,297 | | | 28,738 | |
| Non-current operating lease liabilities | | | 7,540 | | | 8,047 | |
| Other non-current liabilities | | | 325 | | | 325 | |
| Total liabilities | | | 226,268 | | | 240,177 | |
| Commitments and contingencies (Note 15) | | | | | |
| Shareholders’ equity | | | | | |
| Ordinary shares (par value of $0.000006 per share; 5,000,000,000 shares authorized; 978,197,710 and 977,151,270 shares issued as of March 31, 2024 and December 31, 2023, respectively; 973,285,510 and 972,239,070 shares outstanding as of March 31, 2024 and December 31, 2023, respectively) | | | 6 | | | 6 | |
| Additional paid-in capital | | | 2,993,282 | | | 2,975,302 | |
| Accumulated deficit | | | (2,249,451) | | | (2,195,980) | |
| Accumulated other comprehensive income | | | 39,168 | | | 37,626 | |
| Treasury Stock (at cost, 4,912,200 shares as of both March 31, 2024 and December 31, 2023) | | | (20,836) | | | (20,836) | |
| Total shareholders’ equity | | | 762,169 | | | 796,118 | |
| Total liabilities and shareholders’ equity | | | 988,437 | | | 1,036,295 | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Zai Lab Limited
Unaudited Condensed Consolidated Statements of Comprehensive LossOperations
(in thousands of $)$, except for number of shares and per share data)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Three Months Ended June 30, | | Six Months Ended June 30, |
| | | 2023 | | 2022 | | 2023 | | 2022 |
| | | | | | | | | |
| Net loss | | | (120,895) | | | (137,933) | | | (170,039) | | | (220,327) | |
| Other comprehensive income, net of tax of nil: | | | | | | | | | |
| Foreign currency translation adjustments | | | 34,908 | | | 30,325 | | | 26,495 | | | 28,132 | |
| Comprehensive loss | | | (85,987) | | | (107,608) | | | (143,544) | | | (192,195) | |
| | | | | | | | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, | | |
| Notes | | 2024 | | 2023 | | | | |
| | | | | | | | | |
| Revenue | 6 | | 87,149 | | | 62,797 | | | | | |
| Expenses | | | | | | | | | |
| Cost of sales | | | (33,619) | | | (21,337) | | | | | |
| Research and development | | | (54,645) | | | (48,472) | | | | | |
| Selling, general, and administrative | | | (69,194) | | | (62,510) | | | | | |
| Loss from operations | | | (70,309) | | | (69,522) | | | | | |
| Interest income | | | 9,658 | | | 10,232 | | | | | |
| Interest expenses | | | (113) | | | — | | | | | |
| Foreign currency (losses) gains | | | (2,068) | | | 8,912 | | | | | |
| Other income, net | 13 | | 9,361 | | | 1,234 | | | | | |
| Loss before income tax | | | (53,471) | | | (49,144) | | | | | |
| Income tax expense | 7 | | — | | | — | | | | | |
| Net loss | | | (53,471) | | | (49,144) | | | | | |
| Loss per share - basic and diluted | 8 | | (0.05) | | | (0.05) | | | | | |
| Weighted-average shares used in calculating net loss per ordinary share - basic and diluted | | | 973,145,760 | | | 961,444,780 | | | | | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Zai Lab Limited
Unaudited Condensed Consolidated Statements of Comprehensive Loss
(in thousands of $)
| | | | | | | | | | | | | | | | | | | | | |
| | | Three Months Ended March 31, | | |
| | | 2024 | | 2023 | | | | |
| Net loss | | | (53,471) | | | (49,144) | | | | | |
| Other comprehensive income, net of tax of nil: | | | | | | | | | |
| Foreign currency translation adjustments | | | 1,542 | | | (8,413) | | | | | |
| Comprehensive loss | | | (51,929) | | | (57,557) | | | | | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Zai Lab Limited
Unaudited Condensed Consolidated Statements of Shareholders’ Equity
(in thousands of $, except for number of shares)
| | Ordinary Shares | | | Ordinary Shares | | Additional
paid
in capital | | Accumulated
deficit | | Accumulated
other
comprehensive
income (loss) | | Treasury Stock | | Total |
| Number
of
Shares | |
| Balance at December 31, 2023 | |
| Balance at December 31, 2023 | |
| Balance at December 31, 2023 | |
| Issuance of ordinary shares upon vesting of restricted shares | |
| | Share-based compensation | |
| | Share-based compensation | |
| | Share-based compensation | |
| Net loss | |
| Foreign currency translation | |
| Balance at March 31, 2024 | |
| | | Ordinary Shares | | Additional
paid
in capital | | Accumulated
deficit | | Accumulated
other
comprehensive
income (loss) | | Treasury Stock | | Total |
| | Number
of
Shares | | Amount | | Shares | | Amount | |
| | Balance at December 31, 2022 | 962,455,850 | | | 6 | | | 2,893,120 | | | (1,861,360) | | | 25,685 | | | (2,236,280) | | | (11,856) | | | 1,045,595 | |
| Issuance of ordinary shares upon vesting of restricted shares | 732,040 | | | 0 | | 0 | | — | | | — | | | — | | | — | | | — | |
| Exercise of share options | 4,009,460 | | | 0 | | 1,673 | | | — | | | — | | | — | | | — | | | 1,673 | |
| Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation | — | | | — | | | — | | | — | | | — | | | (1,272,330) | | | (5,130) | | | (5,130) | |
| Share-based compensation | — | | | — | | | 16,661 | | | — | | | — | | | — | | | — | | | 16,661 | |
| Net loss | — | | | — | | | — | | | (49,144) | | | — | | | — | | | — | | | (49,144) | |
| Foreign currency translation | — | | | — | | | — | | | — | | | (8,413) | | | — | | | — | | | (8,413) | |
| Balance at March 31, 2023 | 967,197,350 | | | 6 | | | 2,911,454 | | | (1,910,504) | | | 17,272 | | | (3,508,610) | | | (16,986) | | | 1,001,242 | |
| Issuance of ordinary shares upon vesting of restricted shares | 6,117,040 | | | 0 | | 0 | | — | | | — | | | — | | | — | | | — | |
| Exercise of share options | 41,000 | | | 0 | | 88 | | | — | | | — | | | — | | | — | | | 88 | |
| Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation | — | | | — | | | — | | | — | | | — | | | (1,280,500) | | | (3,540) | | | (3,540) | |
| Share-based compensation | — | | | — | | | 20,511 | | | — | | | — | | | — | | | — | | | 20,511 | |
| Net loss | — | | | — | | | — | | | (120,895) | | | — | | | — | | | — | | | (120,895) | |
| Foreign currency translation | — | | | — | | | — | | | — | | | 34,908 | | | — | | | — | | | 34,908 | |
| Balance at June 30, 2023 | 973,355,390 | | | 6 | | | 2,932,053 | | | (2,031,399) | | | 52,180 | | | (4,789,110) | | | (20,526) | | | 932,314 | |
|
| | | Ordinary Shares | | Additional
paid
in capital | | Accumulated
deficit | | Accumulated
other
comprehensive
income (loss) | | Treasury Stock | | Total |
| | Number
of
Shares | | Amount | | Shares | | Amount | |
| | Balance at December 31, 2021 | 955,363,980 | | | 6 | | | 2,825,948 | | | (1,418,074) | | | (23,645) | | | (382,930) | | | (4,279) | | | 1,379,956 | |
| Balance at December 31, 2022 | |
| | Balance at December 31, 2022 | |
| | Balance at December 31, 2022 | |
| Issuance of ordinary shares upon vesting of restricted shares | Issuance of ordinary shares upon vesting of restricted shares | 514,800 | | | 0 | | 0 | | — | | | — | | | — | | | — | | | — | |
| Exercise of share options | Exercise of share options | 1,156,660 | | | 0 | | 297 | | | — | | | — | | | — | | | — | | | 297 | |
| Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation | Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation | — | | | — | | | — | | | — | | | — | | | (15,150) | | | (68) | | | (68) | |
| Share-based compensation | Share-based compensation | — | | | — | | | 12,410 | | | — | | | — | | | — | | | — | | | 12,410 | |
| Net loss | Net loss | — | | | — | | | — | | | (82,394) | | | — | | | — | | | — | | | (82,394) | |
| Foreign currency translation | Foreign currency translation | — | | | — | | | — | | | — | | | (2,193) | | | — | | | — | | | (2,193) | |
| Balance at March 31, 2022 | 957,035,440 | | | 6 | | | 2,838,655 | | | (1,500,468) | | | (25,838) | | | (398,080) | | | (4,347) | | | 1,308,008 | |
| Issuance of ordinary shares upon vesting of restricted shares | 683,700 | | | 0 | | 0 | | — | | | — | | | — | | | — | | | — | |
| Exercise of share options | 2,801,000 | | | 0 | | 4,322 | | | — | | | — | | | — | | | — | | | 4,322 | |
| Receipt of shares netted to satisfy tax withholding obligations related to share-based compensation | — | | | — | | | — | | | — | | | — | | | (1,627,230) | | | (6,782) | | | (6,782) | |
| Share-based compensation | — | | | — | | | 14,225 | | | — | | | — | | | — | | | — | | | 14,225 | |
| Net loss | — | | | — | | | — | | | (137,933) | | | — | | | — | | | — | | | (137,933) | |
| Foreign currency translation | — | | | — | | | — | | | — | | | 30,325 | | | — | | | — | | | 30,325 | |
| Balance at June 30, 2022 | 960,520,140 | | | 6 | | | 2,857,202 | | | (1,638,401) | | | 4,487 | | | (2,025,310) | | | (11,129) | | | 1,212,165 | |
| Balance at March 31, 2023 | |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. “0” in above table means less than 1,000 dollars.
Zai Lab Limited
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands of $)
| | Six Months Ended
June 30, |
| 2023 | | 2022 |
| | Three Months Ended
March 31, | | | Three Months Ended
March 31, |
| 2024 | | | 2024 | | 2023 |
| Cash flows from operating activities | Cash flows from operating activities | | | |
| Net loss | Net loss | (170,039) | | | (220,327) | |
| Net loss | |
| Net loss | |
| Adjustments to reconcile net loss to net cash used in operating activities: | Adjustments to reconcile net loss to net cash used in operating activities: | | | | Adjustments to reconcile net loss to net cash used in operating activities: | | | |
| Allowance for credit loss (gain) | 3 | | | (3) | |
| Allowance for credit losses | |
| Inventory write-down | Inventory write-down | 623 | | | 193 | |
| Depreciation and amortization expenses | Depreciation and amortization expenses | 4,652 | | | 3,874 | |
| Amortization of deferred income | Amortization of deferred income | (1,716) | | | (1,386) | |
| Share-based compensation | Share-based compensation | 37,172 | | | 26,634 | |
| Share of loss from equity method investment | — | | | 221 | |
| Loss from fair value changes of equity investment with readily determinable fair value | 1,304 | | | 12,556 | |
| Loss (gain) on disposal of property and equipment | 260 | | | (11) | |
| Gain on disposal of land use right | (404) | | | — | |
| Gain from fair value changes of equity investment with readily determinable fair value | |
| Losses on disposal of property and equipment | |
| Noncash lease expenses | Noncash lease expenses | 4,383 | | | 3,825 | |
| Gain from sale of intellectual property | (10,000) | | | — | |
| Foreign currency remeasurement loss | 31,167 | | | 32,610 | |
| Debt issuance costs | |
| Foreign currency remeasurement impact | |
| Changes in operating assets and liabilities: | Changes in operating assets and liabilities: | | | | Changes in operating assets and liabilities: | | | |
| Accounts receivable | Accounts receivable | (8,863) | | | 20,422 | |
| Notes receivable | Notes receivable | (12,714) | | | (3,633) | |
| Inventories | Inventories | (6,627) | | | (4,582) | |
| Prepayments and other current assets | Prepayments and other current assets | 87 | | | 48 | |
| Long-term deposits | Long-term deposits | (184) | | | (78) | |
| Value added tax recoverable | — | | | 23,602 | |
| Accounts payable | Accounts payable | 3,037 | | | (17,718) | |
| Other current liabilities | Other current liabilities | (6,761) | | | (3,100) | |
| Operating lease liabilities | Operating lease liabilities | (3,596) | | | (3,849) | |
| Deferred income | Deferred income | 9,902 | | | (1,325) | |
| Other non-current liabilities | Other non-current liabilities | 325 | | | — | |
| Net cash used in operating activities | Net cash used in operating activities | (127,989) | | | (132,027) | |
| Cash flows from investing activities | Cash flows from investing activities | | | | Cash flows from investing activities | | | |
| Purchases of short-term investments | Purchases of short-term investments | (100,000) | | | (260,274) | |
| Proceeds from maturity of short-term investment | Proceeds from maturity of short-term investment | 84,500 | | | 130,000 | |
| Purchase of property and equipment | (5,234) | | | (13,488) | |
| Purchases of property and equipment | |
| Proceeds from the sale of property and equipment | Proceeds from the sale of property and equipment | 112 | | | — | |
| Purchase of intangible assets | (630) | | | (107) | |
| Proceeds from sale of intellectual property | 10,000 | | | — | |
| Net cash used in investing activities | (11,252) | | | (143,869) | |
| Acquisition of intangible assets | |
| Net cash provided by (used in) investing activities | |
| Cash flows from financing activities | Cash flows from financing activities | | | | Cash flows from financing activities | | | |
| Proceeds from short-term debts | |
| Payments of debt issuance costs | |
| Proceeds from exercises of stock options | Proceeds from exercises of stock options | 1,762 | | | 4,619 | |
| Taxes paid related to settlement of equity awards | Taxes paid related to settlement of equity awards | (7,141) | | | (6,859) | |
| Net cash used in financing activities | (5,379) | | | (2,240) | |
| Net cash provided by (used in) financing activities | |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (3,707) | | | (5,144) | |
| Net decrease in cash, cash equivalents and restricted cash | Net decrease in cash, cash equivalents and restricted cash | (148,327) | | | (283,280) | |
| Cash, cash equivalents and restricted cash - beginning of period | Cash, cash equivalents and restricted cash - beginning of period | 1,009,273 | | | 964,903 | |
| Cash, cash equivalents and restricted cash - end of period | Cash, cash equivalents and restricted cash - end of period | 860,946 | | | 681,623 | |
| Supplemental disclosure on non-cash investing and financing activities | Supplemental disclosure on non-cash investing and financing activities | | | | Supplemental disclosure on non-cash investing and financing activities | | | |
| Payables for purchase of property and equipment | Payables for purchase of property and equipment | 4,344 | | | 1,661 | |
| Payables for intangible assets | 96 | | | 270 | |
| Payables for treasury stock | 1,531 | | | 17 | |
| Payables for acquisition of intangible assets | |
| Receivables for stock option exercise under equity incentive plans | Receivables for stock option exercise under equity incentive plans | — | | | 12 | |
| Right-of-use asset acquired under operating leases | Right-of-use asset acquired under operating leases | 3,313 | | | 8,451 | |
Receivables for disposal of land use right
| 3,867 | | | — | |
| Receivables for disposal of property and equipment | |
| Supplemental disclosure of cash flow information | Supplemental disclosure of cash flow information | | | | Supplemental disclosure of cash flow information | | | |
| Cash and cash equivalents | 859,155 | | | 680,820 | |
| Restricted cash, non-current | 1,791 | | | 803 | |
| Total cash and cash equivalents and restricted cash | 860,946 | | | 681,623 | |
| Cash paid for interest | |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
1. Organization and Principal Activities
Zai Lab Limited was incorporated on March 28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Act of the Cayman Islands (as amended). Zai Lab Limited and its subsidiaries (collectively referred to as the “Company”) are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs including in the areas of oncology, autoimmune disorders, infectious diseases,disease, and neuroscience.
The Company’s principal operations and geographic markets are in Greater China. The Company has a substantial presence in Greater China and the United States. The accompanying unaudited condensed consolidated financial statements are the financial statements of the Company.
2. Basis of Presentation and Consolidation and Significant Accounting Policies
(a) Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States (“U.S. GAAP”), and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”), regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this report should be read in conjunction with the consolidated financial statements and accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 20222023 (the “2022“2023 Annual Report”). The December 31, 20222023 condensed consolidated balance sheet data included in this report were derived from the audited financial statements in the 20222023 Annual Report.
In the third quarter of 2022, we began to separately present the amount of foreign currency remeasurement gain (loss) on our statements of cash flows. This amount was previously included in changes in other current liabilities. This change did not have any impact on net cash used in operating activities. Corresponding amounts in the prior periods of the condensed consolidated financial statement have been presented to conform to the current period presentation.
The accompanying condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to present fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results for the year ending December 31, 2023.2024.
(b) Principles of Consolidation
The unaudited condensed consolidated financial statements include the financial statementsaccounts of the Company.Zai Lab Limited and its subsidiaries, which are wholly owned. All intercompany transactions and balances are eliminated upon consolidation.
(c) Use of Estimates
The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, accrual of rebates, recognition of research and development expenses, to the appropriate financial reporting period based on the progress of the research and development projects, fair value of share-based compensation expenses, and recoverability of deferred tax assets. These estimates, judgments, and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Actual results could differ from these estimates.
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
(d) Fair Value Measurements
Equity investments with readily determinable fair value are measured using level 1 inputs and were $5.1$14.1 million and $6.4$9.2 million as of June 30, 2023March 31, 2024 and December 31, 2022,2023, respectively. The unrealized gains and losses from fair value changes are recognized in other expenses,income, net in the condensed consolidated statements of operations.
Financial instruments of the Company primarily include cash and cash equivalents, andcurrent restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, non-current restricted cash, accounts payable, short-term debts, and other current liabilities. As of June 30, 2023March 31, 2024 and December 31, 2022,2023, the carrying values of cash and cash equivalents, current restricted cash, short-term investments, accounts receivable, notes receivable, prepayments and other current assets, accounts payable, short-term debts, and other current liabilities approximated their fair values due to the short-term maturity of these instruments, and the carrying value of notes receivable and non-current restricted cash approximated itstheir fair value based on the nature of the assessment of the ability to recover these amounts.
(e) Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU requires all public entities, including public entities with a single reportable segment, to disclose the title and position of the Chief Operating Decision Maker (“CODM”) and the significant segment expenses and any additional measures of a segment’s profit or loss used by the CODM to allocate resources and assess performance. This ASU is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and for interim periods beginning after December 15, 2024. Early adoption is permitted. The Company hasis currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2024.
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740). This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. This ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is permitted. This ASU will result in additional disclosure in the consolidated financial statements, once adopted. The Company is currently evaluating the impact of this ASU and expects to adopt it for the year ending December 31, 2025.
The Company did not adoptedadopt any new accounting standards since December 31, 2022.in the first quarter of 2024 that had a material impact on the Consolidated Financial Statements. For a discussion ofadditional information on the Company’s significant accounting policies, see the discussion in Note 2 above andrefer to the notes to the consolidated financial statements in the 20222023 Annual Report.Report.
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
3. Cash and Cash Equivalents
The following table presents the Company’s cash and cash equivalents ($ in thousands):
| | March 31, 2024 | | | March 31, 2024 | | December 31, 2023 |
| | June 30, 2023 | | December 31, 2022 |
| | Cash | |
| Cash | |
| Cash | Cash | 858,089 | | | 1,007,423 | |
| Cash equivalents (i) | Cash equivalents (i) | 1,066 | | | 1,047 | |
| | | 859,155 | | | 1,008,470 | |
| Denominated in: | Denominated in: | | | | Denominated in: | | | |
| US$ | US$ | 832,974 | | | 957,824 | |
| RMB (ii) | 21,968 | | | 45,486 | |
| Renminbi (“RMB”) (ii) | |
| Hong Kong dollar (“HK$”) | Hong Kong dollar (“HK$”) | 3,485 | | | 4,378 | |
| Australian dollar (“A$”) | Australian dollar (“A$”) | 578 | | | 598 | |
| Taiwan dollar (“TW$”) | Taiwan dollar (“TW$”) | 150 | | | 184 | |
| 859,155 | | | 1,008,470 | |
| 650,780 | |
(i)Cash equivalents represent short-term and highly liquid investments in a money market fund.
(ii)Certain cash and bank balances denominated in RMB were deposited with banks in mainland China. The conversion of these RMB denominatedRMB-denominated balances into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the Chinese government.
4. Inventories, Net
The following table presents the Company’s inventories, net ($ in thousands):
| | | | | | | | | | | |
| June 30, 2023 | | December 31, 2022 |
| | | |
| Finished goods | 16,687 | | | 12,156 | |
| Raw materials | 19,320 | | | 19,029 | |
| Work in progress | 346 | | | 436 | |
| Inventories, net | 36,353 | | | 31,621 | |
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
| | | | | | | | | | | |
| March 31, 2024 | | December 31, 2023 |
| | | |
| Finished goods | 19,076 | | | 22,702 | |
| Raw materials | 16,675 | | | 17,655 | |
| Work in progress | 2,100 | | | 4,470 | |
| Inventories, net | 37,851 | | | 44,827 | |
The Company writes down inventory for any excess or obsolete inventories or when the Company believes that the net realizable value of inventories is less than the carrying value. The Company recorded write-downs in inventory, which were included in cost of sales, of $0.2insignificant amount and $0.4 million in the first quarter of 2024 and $0.6 million during the three and six months ended June 30, 2023, respectively, and $0.1 million and $0.2 million during the three and six months ended June 30, 2022 respectively.
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
5. Property and Equipment, Net
The following table presents the components of the Company’s property and equipment, net ($ in thousands):
| | March 31, 2024 | | | March 31, 2024 | | December 31, 2023 |
| | June 30, 2023 | | December 31, 2022 |
| | Office equipment | |
| Office equipment | |
| Office equipment | Office equipment | 985 | | | 977 | |
| Electronic equipment | Electronic equipment | 8,457 | | | 7,416 | |
| Vehicle | Vehicle | 195 | | | 202 | |
| Laboratory equipment | Laboratory equipment | 19,672 | | | 18,726 | |
| Manufacturing equipment | Manufacturing equipment | 16,595 | | | 17,055 | |
| Leasehold improvements | Leasehold improvements | 11,036 | | | 11,300 | |
| Construction in progress | Construction in progress | 25,092 | | | 24,251 | |
| 82,032 | | | 79,927 | |
| 84,574 | |
| Less: accumulated depreciation | Less: accumulated depreciation | (25,622) | | | (22,064) | |
| Property and equipment, net | Property and equipment, net | 56,410 | | | 57,863 | |
Depreciation expense was $1.8$2.2 million and $4.3$2.5 million forin the threefirst quarter of 2024 and six months ended June 30, 2023, respectively, and $1.7 million and $3.6 million for the three and six months ended June 30, 2022, respectively.
6. Revenue
Product Revenue
The Company’s product revenue is primarily derived from the sales of ZEJULA, Optune, QINLOCK, and NUZYRAits commercial products primarily in mainland China and Hong Kong.China. The table below presents the Company’s gross and net product revenue ($ in thousands):
| | Three Months Ended March 31, | |
| Three Months Ended March 31, | |
| Three Months Ended March 31, | |
| 2024 | |
| 2024 | |
| 2024 | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| Product revenue - gross | |
| | 2023 | | 2022 | | 2023 | | 2022 |
| Product revenue - gross | |
| | Product revenue - gross | Product revenue - gross | 75,010 | | | 54,339 | | | 146,222 | | | 107,649 | |
| Less: Rebates and sales returns | Less: Rebates and sales returns | (6,146) | | | (6,764) | | | (14,561) | | | (13,979) | |
| Less: Rebates and sales returns | |
| Less: Rebates and sales returns | |
| Product revenue - net | Product revenue - net | 68,864 | | | 47,575 | | | 131,661 | | | 93,670 | |
| Product revenue - net | |
| Product revenue - net | |
Sales rebates are offered to distributors in mainland China, and the amounts are recorded as a reduction of revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.
The following table presents the Company’s net revenue by product ($ in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2024 | | 2023 | | | | |
| | | | | | | |
| ZEJULA | 45,501 | | | 42,680 | | | | | |
| OPTUNE | 12,480 | | | 13,342 | | | | | |
| QINLOCK | 6,093 | | | 1,306 | | | | | |
| NUZYRA | 9,913 | | | 5,469 | | | | | |
| VYVGART | 13,162 | | | — | | | | | |
| Product revenue - net | 87,149 | | | 62,797 | | | | | |
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
The following table presents the Company’s net revenue by product ($ in thousands):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2023 | | 2022 | | 2023 | | 2022 |
| | | | | | | |
| ZEJULA | 42,957 | | | 34,052 | | | 85,637 | | | 63,649 | |
| Optune | 13,692 | | | 11,592 | | | 27,034 | | | 24,389 | |
| QINLOCK | 7,527 | | | 623 | | | 8,833 | | | 3,582 | |
| NUZYRA | 4,636 | | | 1,308 | | | 10,105 | | | 2,050 | |
| VYVGART | 52 | | | — | | | 52 | | | — | |
| Product revenue - net | 68,864 | | | 47,575 | | | 131,661 | | | 93,670 | |
7. Income Tax
No provision for income taxes has been required to be accrued because the Company and all of its subsidiaries areis in a cumulative loss positionsposition for the periods presented.
The Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of June 30, 2023March 31, 2024 and December 31, 2022.2023. No unrecognized tax benefits and related interest and penalties were recorded in the periods presented.
8. Other Current Liabilities
The following table presents the Company’s other current liabilities ($ in thousands):
| | | | | | | | | | | |
| June 30, 2023 | | December 31, 2022 |
| | | |
| Payroll | 18,976 | | | 31,689 | |
| Accrued professional service fee | 7,922 | | | 4,080 | |
| Payables for purchase of property and equipment | 4,344 | | | 5,269 | |
| Accrued rebate to distributors | 8,514 | | | 8,443 | |
| Tax payables | 15,768 | | | 13,283 | |
| Others (i) | 3,500 | | | 4,054 | |
| Total | 59,024 | | | 66,818 | |
(i)Others mainly include accrued travel and business-related expenses.
9. Loss Per Share
The following table presents the computation of the basic and diluted net loss per share ($ in thousands, except share and per share data):
| | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended June 30, | | Six Months Ended June 30, |
| 2023 | | 2022 | | 2023 | | 2022 |
| | | | | | | |
| Numerator: | | | | | | | |
| Net loss attributable to ordinary shareholders | (120,895) | | | (137,933) | | | (170,039) | | | (220,327) | |
| Denominator: | | | | | | | |
| Weighted average number of ordinary shares - basic and diluted | 964,817,310 | | | 957,684,820 | | | 963,140,360 | | | 956,603,250 | |
| Net loss per share - basic and diluted | (0.13) | | | (0.14) | | | (0.18) | | | (0.23) | |
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2024 | | 2023 | | | | |
| | | | | | | |
| Numerator: | | | | | | | |
| Net loss | (53,471) | | | (49,144) | | | | | |
| Denominator: | | | | | | | |
| Weighted average number of ordinary shares - basic and diluted | 973,145,760 | | | 961,444,780 | | | | | |
| Net loss per share - basic and diluted | (0.05) | | | (0.05) | | | | | |
As a result of the Company’s net loss forin the threefirst quarter of 2024 and six months ended June 30, 2023, and 2022, share options and non-vested restricted shares outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. | | June 30, |
| 2023 | | 2022 |
| March 31, | | | March 31, |
| 2024 | | | 2024 | | 2023 |
| Share options | Share options | 108,322,600 | | | 91,546,280 | |
| Non-vested restricted shares | Non-vested restricted shares | 33,462,670 | | | 34,356,250 | |
9. Borrowings
In February 2024, the Company entered into certain debt arrangements with the Bank of China, SPD Bank, and Ningbo Bank to support its working capital needs in mainland China. The following table presents the Company’s short-term debts as of March 31, 2024 ($ in thousands): | | | | | | | | | | | |
| Weighted average interest rate per annum | | March 31, 2024 |
| Bank of China Working Capital Loan | 2.95 | % | | 34,179 | |
| SPD Bank Working Capital Loan | 3.45 | % | | 14,094 | |
| Total short-term debts | 3.10 | % | | 48,273 | |
Bank of China Working Capital Loan Facility
On February 5, 2024, the Company entered into an uncommitted facility letter with the Bank of China (Hong Kong) Limited (the “BOC HK”) pursuant to which the BOC HK will provide standby letters of credit for loans of up to $100.0 million for a term of one year. In connection with this agreement, the Company paid a one-time, non-refundable fee of $0.7 million. The Company also maintained restricted deposits of $100.0 million, which are presented as restricted cash-current on the condensed consolidated balance sheet, to secure the standby letters of credit. On February 6, 2024, upon the
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
Company’s application, the BOC HK provided a standby letter of credit in favor of the Bank of China Pudong Development Zone Branch (the “BOC Pudong Branch”) for $50.0 million which are or may become payable by the Company’s wholly-owned subsidiary, Zai Lab (Shanghai) Co., Ltd. (“Zai Lab Shanghai”), and Zai Lab Shanghai subsequently entered into a working capital loan contract with the BOC Pudong Branch on February 7, 2024 for a loan of RMB340.0 million (approximately $47.8 million), of which an aggregate principal amount of RMB242.5 million (approximately $34.2 million) was withdrawn and outstanding as of March 31, 2024. Each working capital loan withdrawal has a one-year term and is subject to a floating interest rate of approximately 2.95% initially, and is subject to adjustment every six months.
SPD Bank Working Capital Loan Facility
On February 6, 2024, the Company entered into a maximum-amount guarantee contract with the Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch (the “SPD Bank”) pursuant to which the Company will guarantee working capital loans of up to RMB300.0 million (approximately $42.0 million) from SPD Bank to Zai Lab Shanghai over a three-year period. In the first quarter of 2024, Zai Lab Shanghai has entered into working capital loan contracts with SPD Bank under this debt facility for an aggregate principal amount of RMB100.0 million (approximately $14.1 million). These working capital loans have one-year terms and are subject to a fixed interest rate of 3.45%.
Ningbo Bank Working Capital Loan Facility
On February 6, 2024, the Company’s wholly-owned subsidiary, Zai Lab (Suzhou) Co., Ltd. (“Zai Lab Suzhou”), entered into a maximum credit contract with Bank of Ningbo Co., Ltd. Suzhou Sub-branch (“Ningbo Bank”) as well as an Electronic Commercial Draft Discounting Master Agreement and Online Working Capital Loan Master Agreement (collectively, the “Ningbo Bank Agreements”). The Ningbo Bank Agreements permit Zai Lab Suzhou to utilize, including through discounting or working capital loan agreements and subject to the terms and conditions in related master agreements, up to RMB230.3 million (approximately $32.4 million), of which the Company is authorized to utilize up to RMB160.0 million (approximately $22.5 million). In connection with the arrangements described in the Ningbo Bank Agreements, Zai Lab Suzhou agreed to pledge interests in certain real property it owns in Suzhou. As of March 31, 2024, Zai Lab Suzhou has not entered into any discounting arrangements or working capital loans under this Ningbo Bank working capital loan facility.
10. Related Party TransactionsOther Current Liabilities
The following table presents the Company’s other current liabilities ($ in thousands):
| | | | | | | | | | | |
| March 31, 2024 | | December 31, 2023 |
| | | |
| Accrued payroll | 11,920 | | | 33,711 | |
| Accrued professional service fee | 3,478 | | | 7,520 | |
| Payables for purchase of property and equipment | 2,481 | | | 2,474 | |
| Accrued rebate to distributors | 20,593 | | | 16,926 | |
| Tax payables | 6,910 | | | 16,988 | |
| Other (i) | 2,794 | | | 5,353 | |
| Total | 48,176 | | | 82,972 | |
(i)Other mainly includes accrued travel and business-related expenses.
The Company incurred research and development expenses for product research and development services provided by MEDx (Suzhou) Translational Medicine Co., Ltd (“MEDx”), over which an immediate family member of our Chief Executive Officer and Chairperson ofZai Lab Limited
Notes to the Board held significant influence. The Company incurred development expenses with MEDx of insignificant amounts during the three and six months ended June 30, 2023 and $0.2 million and $0.3 million during the three and six months ended June 30, 2022, respectively.unaudited condensed consolidated financial statements
11. Share-Based Compensation
During the six months ended June 30, 2023,first quarter of 2024, the Company granted share options to purchase up to 22,776,380398,000 ordinary shares and restricted shares representing 8,326,080370,500 ordinary shares under the 2022 Plan. The share options granted have a contractual term of ten years. Share options granted since April 2023 generally vest ratably over a four-year period, and share options granted prior to April 2023 generally vest ratably over a five-year period, with 25% or 20% of the awards vesting on each anniversary of the grant date, respectively, subject to continued employmentemployment/service with the Company on the vesting date. For a description of the Company’s equity incentive plans and more details on the terms of the share-based awards, see Note 15 to our 2022 Annual Report.
During the six months ended June 30, 2023, the share options were granted at exercise prices ranging from $3.35 per share to $3.99 per share. The share options granted were valued using the Black-Scholes model, and the weighted-average grant-date fair value was $2.23 per share. The restricted shares granted generally vest ratably over a specified period on the anniversary of the grant date, subject to continued employment/service with the Company on the vesting date. For a description of the Company’s equity incentive plans and more details on the terms of the share-based awards, refer to Note 15 of the 2023 Annual Report.
The following table presents the share-based compensation expense that has been reported in the Company’s condensed consolidated statements of operations and comprehensive loss as follows ($ in thousands):
| | Three Months Ended March 31, | |
| Three Months Ended March 31, | |
| Three Months Ended March 31, | |
| 2024 | |
| 2024 | |
| 2024 | |
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| Selling, general and administrative | |
| | 2023 | | 2022 | | 2023 | | 2022 |
| Selling, general and administrative | |
| | Selling, general and administrative | Selling, general and administrative | 11,776 | | | 8,931 | | | 21,839 | | | 15,923 | |
| Research and development | Research and development | 8,735 | | | 5,294 | | | 15,333 | | | 10,712 | |
| Research and development | |
| Research and development | |
| Total | Total | 20,511 | | | 14,225 | | | 37,172 | | | 26,635 | |
| Total | |
| Total | |
As of June 30, 2023,March 31, 2024, there was unrecognized share-based compensation expense related to unvested share options and unvested restricted shares of $129.2$93.2 million and $130.9$92.0 million, respectively, which the Company expects to recognize over a weighted-average period of 3.452.89 years and 3.212.54 years, respectively.
12. License and Collaboration Agreements
The Company has entered into various license and collaboration agreements with third parties to develop and commercialize product candidates.
Zai Lab Limited
Notes to the unaudited condensed consolidated financial statements
Significant License and Collaboration Arrangements
For a description of the material terms of the Company’s significant license and collaboration agreements, see Note 16 to our 2022 of the 2023 Annual Report. DuringIn the six months ended June 30, 2023,first quarter of 2024, the Company did not enter into any new significant license and collaboration agreements or collaboration agreements. The following includes a description of payments or accruals related to upfront orincur any milestone fees under our existing significant license and collaboration agreements during the six months ended June 30, 2023.
License and Collaboration Agreement with Entasis Therapeutics Holdings Inc.(“Entasis”) (SUL-DUR)
Under the terms of our license and collaboration agreement with Entasis for SUL-DUR, the Company accrued a $3.0 million development milestone in the second quarter of 2023, and the additional aggregate amount the Company may be required to pay for development, regulatory, and sales-based milestones decreased to $88.6 million.
License Agreement with BMS (Formerly Turning Point Therapeutics Inc (“Turning Point”)) (Repotrectinib)
Under the terms of our license agreement with BMS for reprotrectinib, the Company accrued a $5.0 million development milestone in the second quarter of 2023, and the additional aggregate amount the Company may be required to pay for development, regulatory, and sales-based milestones decreased to $141.0 million.
Other License and Collaboration Arrangements That Are Not Individually Significant
The Company made an upfront payment of $10.0 million in the second quarter of 2023 for a new strategic partnership and global license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. for an early-stage next generation DLL3 ADC program, ZL-1310.agreements.
13. Other Expenses,Income, Net
The following table presents the Company’s other expenses,income, net ($ in thousands):
| | Three Months Ended June 30, | | Six Months Ended June 30, |
| 2023 | | 2022 | | 2023 | | 2022 |
| Three Months Ended March 31, | |
| Three Months Ended March 31, | |
| Three Months Ended March 31, | |
| 2024 | |
| 2024 | |
| 2024 | |
| Government grants | Government grants | 83 | | | 50 | | | 83 | | | 1,627 | |
| Loss on equity investments with readily determinable fair value | (1,744) | | | (5,617) | | | (1,304) | | | (12,556) | |
| Government grants | |
| Government grants | |
| Gain on equity investments with readily determinable fair value | |
| Gain on equity investments with readily determinable fair value | |
| Gain on equity investments with readily determinable fair value | |
| Others miscellaneous gain | |
| Others miscellaneous gain | |
| Others miscellaneous gain | Others miscellaneous gain | 256 | | | 70 | | | 1,050 | | | 551 | |
| Total | Total | (1,405) | | | (5,497) | | | (171) | | | (10,378) | |
| Total | |
| Total | |
14. Restricted Net Assets
The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its Chinese subsidiaries. Relevant Chinese laws and regulations permit payments of dividends by the Company’s Chinese subsidiaries only out of its retained earnings, if any, as determined in accordance with Chinese accounting standards and
regulations. The results of operations reflected in the unaudited condensed consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory financial statements of the Company’s Chinese subsidiaries.
In accordance with the Company Law of the People’s Republic of China, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s Chinese statutory accounts. A domestic enterprise may provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise’s Chinese statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s Chinese subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits.
No appropriation to statutory reserves was made duringin the threefirst quarter of 2024 and six months ended June 30, 2023 and 2022 because the Chinese subsidiaries had substantial losses during such periods.
As a result of these Chinese laws and regulations, subject to the limits discussed above that require annual appropriations of 10% of after-tax profit to be set aside, prior to payment of dividends, as a general reserve fund, the Company’s Chinese subsidiaries are restricted in their ability to transfer out a portion of their net assets.
Foreign exchange and other regulation in mainland China may further restrict the Company’s Chinese subsidiaries in mainland China from transferring out funds in the form of dividends, loans, and advances. As of June 30, 2023March 31, 2024 and December 31, 2022,2023, amounts restricted arewere the paid-in capital of the Company’s Chinese subsidiaries in mainland China, which both amounted to $456.0$506.0 million.
15. Commitments and Contingencies
(a) Purchase Commitments
The Company’s commitments related to purchase of property and equipment contracted but not yet reflected in the unaudited condensed consolidated financial statements were $3.9$1.1 million as of June 30, 2023March 31, 2024 and were expected to be incurred within one year.
(b) Legal Proceedings
The Company is not currently a party to any material legal proceedings.
(c) Indemnifications
In the normal course of business, the Company enters into agreements that indemnify others for certain liabilities that may arise in connection with a transaction or certain events and activities. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.Operations
TheYou should read the following discussion and analysis of our financial condition and results of operations should be read in conjunctiontogether with our 20222023 Annual Report and our unaudited condensed consolidated financial statements and the accompanying notes for the three and six months ended June 30, 2023first quarter of 2024 included in Item 1. Financial Statements.Statements.
Overview
We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases,disease, and neuroscience. We intend to leverage our competencies and resources to positively impact human health in Greater China and worldwide. We currently have five commercial products – ZEJULA®, OPTUNE, QINLOCK®, NUZYRA®, and VYVGART® – that have received marketing approval and that we have commercially launched in one or more territories in Greater China (our “commercial products”China. OPTUNE refers to Tumor Treating Fields devices marketed under various brand names, including OPTUNE GIO® for glioblastoma multiforme (“GBM”). We have commercially launched four of those products – ZEJULA®, Optune®, QINLOCK®, and NUZYRA® – and we expect to commercially launch VYVGART® later this year. We also have thirteenmultiple programs in late-stage product development and a number of ongoing pivotal trials across our portfolio.
Since our inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from funding our research and development programs and selling, general and administrative costs associated with our operations. Developing high quality product candidates requires significant investment in our research and development activities over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. Our ability to generate profits and positive cash flow from operations over the next several years depends upon our ability to successfully market our commercial products and to successfully expand the indications for these products and develop and commercialize our other product candidates. WeAs discussed further below, we expect to continue to incur substantial expensescosts related to our research and development activities. For example, our licensing and collaboration agreements may require us to make upfront payments upon our entry into such agreements and milestone payments upon the achievement of certain development, regulatory, and sales-based milestones as well as certain royalties at tiered percentage rates based on annual net sales of the licensed products in the licensed territories. In addition, we expect to incur substantial costs related to the commercialization of our product candidates, in particular during the early launch phase.activities.
As we pursue our strategy of growth and development,corporate strategic goals, we anticipate that our financial results will fluctuate from quarter to quarter and year to year depending in part on the balance between the success of our commercial products and the level of our research and development expenses. We cannot predict whether or when products in our pipeline, including new indications for our current commercial products,product candidates will receive regulatory approval. Further, if we receive such regulatory approval, we cannot predict whether or when we may be able to successfully commercialize such product or whether or when such product may become profitable.
Recent Developments
Commercial Products
We continued to increase netNet product revenuesrevenue was $87.1 million for each of our commercial products in the secondfirst quarter of 2023,2024, an increase of 39% compared to the second quarter of 2022,prior year period, primarily driven by the increased sales volume including from VYVGART, our fifth commercial product that was launched in September 2023. We are expanding access for ZEJULA, QINLOCK, and NUZYRAto our products, such as a result of their inclusion in thethrough National Reimbursement Drug List (“NRDL”) listings and for Optuneinclusions in hospital formularies as a result of increasedwell as through supplemental insurance plan coverage.
We are also received the following regulatory approvals for our commercial products during the second quarter of 2023:
•Optune for GBM in Taiwan: In May 2023, the Taiwan Food and Drug Administration approved the Marketing Authorization Application (“MAA”) for Optune for the treatment of patients with glioblastoma multiforme (“GBM”).
•VYVGART for gMG in mainland China: In June 2023, we received approval from the NMPA for the Biologics License Application (“BLA”) for VYVGART (efgartigimod alfa injection), a first-in-class neonatal Fc receptor (“FcRn”) antagonist, as an add on standard therapy for the treatment of adult patients with generalized myasthenia gravis (“gMG”) who are anti-acetylcholine receptor (“AChR”) antibody positive. We expect to commercially launch VYVGART in mainland China later this year.
enhancing brand awareness through outreach efforts.Product Candidates
We continued to advance our product candidates through our research and development and commercial operations,activities, including the following developments with respect to our clinical trials and regulatory approvals:
Oncology
•ZEJULA (niraparib, PARP): In July 2023, we announced the publication in JAMA Oncology of data from the pivotal Phase III PRIME study evaluating ZEJULA as a first-line maintenance therapy in Chinese patients with newly diagnosed advanced ovarian cancer and demonstrating that an individual starting dose (“ISD”) of 200 or 300mg based on baseline bodyweight and platelet count can bring significant benefit to patients with an improved safety and tolerability profile of ZEJULA compared to a fixed 300mg starting dose. The data demonstrated that maintenance treatment with ZEJULA can significantly extend progression-free survival (“PFS”) versus a placebo and can reduce the risk of disease progression or death by 55% among patients with newly diagnosed advanced ovarian cancer, regardless of postoperative residual disease or biomarker status. For example, with a median follow-up of 27.5 months, median PFS (“mPFS”) with ZEJULA versus placebo in the intention-to-treat (“ITT”) population was 24.8 versus 8.3 months (hazard ratio (“HR”), 0.45; 95% confidence internal (“CI”), 0.34–0.60; p<.001). At the time of data cut-off, overall survival (“OS”) data were not yet mature in the ITT population. Utilization of an individual starting dose demonstrated a tolerable safety profile in the maintenance setting. Grade ≥3 treatment-emergent adverse events (“TEAEs”) and serious adverse events (“SAEs”) were reported in 54.5% versus 17.8% and 18.8% vs 8.5% in ZEJULA-treated and placebo-treated patient, respectively. Similar proportions of ZEJULA-treated and placebo-treated patients (6.7% vs 5.4%) discontinued therapy due to TEAEs. The findings are consistent with prior studies that indicate that ZEJULA monotherapy as first-line maintenance treatment can provide statistically and clinically meaningful benefit in a broad population of patients, regardless of postoperative residual disease or biomarker status.
•Tumor Treating Fields (TTFields or Optune):
◦NSCLC:Fields: In June 2023, we announced withMarch 2024, our partner NovoCure Limited (“NovoCure”) announced that the Phase III LUNARMETIS clinical trial demonstratedmet its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields therapy and clinically meaningful extensionsupportive care compared to supportive care alone in OS forthe treatment of patients with metastatic1-10 brain metastases from non-small cell lung cancer (“NSCLC”) after platinum-based therapies.following stereotactic radiosurgery. The LUNARMETIS trial met its primary endpoint with a statistically significant and clinically meaningful 3-month improvement in median OS when TTFields therapy was added to standard therapies (HR: 0.74, P=0.035). Patients randomized to receive TTFields therapy together with standard therapies (n=137) demonstrated median OS of 13.2 months compared to 9.9 months in patients treated with standard therapies alone (n=139). A profound OS benefit from TTFields therapy was demonstrated in the immune checkpoint inhibitor (“ICI”) subgroup. Patients randomized to receive TTFields therapy and physician’s choice ICI (n=66) demonstrated a median OS of 18.5 months versus 10.8 months in patients treated with ICIs alone (n=68; HR=0.63; P=0.03), and patients randomized to receive TTFields therapy and docetaxel (n=71) had a positive survival trend with a median OS of 11.1 months versus 8.7 months in patients treated with docetaxel alone (n=71). TTFields therapy was well-tolerated with no added systemic toxicities and few grade 3 (no grade 4 or 5) device-related adverse events. NovoCure presented the positive results at the 2023 American Society of Clinical Oncology (“ASCO”) Annual Meeting in June 2023. We participated in the Greater China portion of the study.
◦Pancreatic Cancer: In July 2023, NovoCure announced the results of a pre-specified interim analysis for the Phase III PANOVA-3 clinical trial evaluating the safety and efficacy of TTFields therapy together with nab-paclitaxel and gemcitabine for the treatment of patients with unresectable, locally advanced pancreatic cancer. An independent data monitoring committee (“DMC”) reviewed the safety and efficacy data for all patients in the fully enrolled clinical trial. The interim analysis resulted in a DMC recommendation that the clinical trial proceed to final analysis. Zai Lab participated in the Greater China portion of the study.
•KRAZATI® (adagrasib, KRASG12C): In April 2023 and May 2023, our partner Mirati Therapeutics, Inc. (“Mirati”) announced the inclusion of adagrasib as the only KRASG12C inhibitor in the National Comprehensive Cancer Network (“NCCN”) Guidelines for Central Nervous System (“CNS”) Cancers for patients with KRASG12C-mutated NSCLC with CNS metastases and for KRASG12C-mutation positive pancreatic adenocarcinoma cancer patients, respectively. Also, in April 2023, Mirati presented updated clinical data for adagrasib as a targeted treatment for pancreatic ductal adenocarcinoma, biliary tract cancer,
demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and other solid tumors harboring a KRASG12C mutation at the 2023 American Society of Clinical Oncology (“ASCO”) Plenary series. Data was concurrently publishedsupportive care compared to 11.3 months for patients treated with supportive care alone. We are participating in the Journal of Clinical Oncology. In June 2023, we completed enrollment in China for the global Phase 2 KRYSTAL-7 trial of adagrasib in combination with pembrolizumab as first-line treatment for patients with advanced KRASG12C-mutated NSCLC, and in July 2023, we completed enrollment in China for the global Phase 3 KRYSTAL-10 trial of adagrasib in combination with cetuximab versus chemotherapy in patients with previously treated advanced KRASG12C-mutated colorectal cancer.METIS trial.
•Repotrectinib (ROS1/TRK):Tisotumab Vedotin: In May 2023,April 2024, our partner Bristol Myers Squibb (“BMS”)Pfizer Inc. and Genmab A/S announced that the FDA had accepted its NewU.S. Food and Drug Administration approved the supplemental Biologics License Application (“NDA”)granting full approval for repotrectinib, a next generation tyrosine kinase inhibitor (“TKI”tisotumab vedotin (or TIVDAK®), for the treatment of adult patients with ROS1-positive locally advanced or metastatic NSCLC based on results from the TRIDENT-1 trial. The FDA granted the application priority review and assigned a Prescription Drug User Fee Act (“PDUFA”) date of November 27, 2023. In June 2023, the NMPA accepted our NDA for repotrectinib for the same indications, after granting priority review in May 2023.
•TIVDAK® (Tisotumab Vedotin, Antibody Drug Conjugate (“ADC”)): In April 2023, our partner Seagen Inc. (“Seagen”) presented the interim analysis for the Phase II innovaTV 207 study in head and neck cancer at the 2023 American Association of Cancer Research (“AACR”) Annual Meeting. At data cutoff (November 28, 2022), confirmed objective response rate (“ORR”) was 40% (95% confidence interval (“CI”): 16.3, 67.7), with 1 complete response and 5 partial responses. The safety profile was generally consistent with that observed across TIVDAK monotherapy clinical studies. In addition, in February 2023, Seagen completed global target patient enrollment for the Phase III confirmatory innovaTV 301 study in second- or third-line recurrent or metastatic cervical cancer.cancer with disease progression on or after chemotherapy. We are participating in the global Phase III innovaTV 301 trial and ongoing extension study in Greater China.
•Bemarituzumab (FGFR2b):Adagrasib: In July 2023,We are evaluating the clinical data of the global Phase III KRYSTAL-12 study evaluating adagrasib in previously treated patients with KRASG12C-mutated NSCLC as we enrolleddecide on next steps in the first patientdevelopment of this product across indications.
•Early-Stage Global Oncology Pipeline: We are currently enrolling patients in the United States and Greater China in the global Phase III FORTITUDE-101I study of bemarituzumab plus chemotherapy, versus placebo plus chemotherapy,ZL-1310 (DLL3 ADC) for relapsed and refractory second-line small cell lung cancer who have progressed after platinum-based treatment. We are also enrolling patients in first-line gastric cancerthe United States, Europe, and Greater China in the global Phase I study of ZL-1218 (CCR8) as a single agent and in combination with FGFR2b overexpression.pembrolizumab in patients with advanced solid tumor malignancies.
Autoimmune Disorders, Infectious Diseases,Disease, and Neuroscience
•VYVGART (Efgartigimod, FcRn):
◦gMG:Efgartigimod: In June 2023, our partner argenx BV (“argenx”) announced thatApril 2024, we submitted a supplemental Biologics License Application to the FDA approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection for subcutaneous use in gMG. In July 2023, the NMPA accepted our BLA for efgartigimod alfa injection (subcutaneous injection) (“efgartigimod SC”) injection) for the treatment of adult patients with gMG.
◦CIDP: In July 2023, we and argenx announced positive topline results from the global registrational ADHERE study evaluating VYVGART Hytrulo in adults with chronic inflammatory demyelinating polyneuropathy (“CIDP”). The study met its primary endpoint (p=0.000039), demonstrating a significantly lower risk of relapse with VYVGART Hytrulo compared to placebo. VYVGART Hytrulo demonstrated a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo, and 67% of patients in open-label Stage A demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP. The safety and tolerability profile was consistent with previous clinical trials and the confirmed safety profile of VYVGART. We participated in the Greater China portion of the study.
◦BP: In May 2023, we enrolled the first patient in China in the global Phase II/III BALLAD study of SC efgartigimod in adult patients with bullous pemphigoid (“BP”).
•XACDUROXanomeline-Trospium (KarXT): ® (Sulbactam-Durlobactam or SUL-DUR, Asia Pacific Rights):In May 2023,April 2024, our partner Entasis Therapeutics, Inc. Bristol Myers Squibb (“Entasis”BMS”), a wholly owned subsidiary of Innoviva, Inc., announced thatpresented new interim long-term data from the FDA approved XACDUROPhase III EMERGENT program for the treatment of adultsschizophrenia. In the new interim analysis of long-term efficacy data from the Phase 3 EMERGENT-4 open-label extension trial, KarXT was associated with hospital-acquired bacterial pneumoniasignificant improvement in symptoms of schizophrenia across all efficacy measures at 52 weeks, and ventilator-associated bacterial pneumonia caused by susceptible strainsin the new pooled interim long-term safety and metabolic outcomes from the Phase III EMERGENT-4 and EMERGENT-5 trials, KarXT demonstrated a favorable long-term metabolic profile where most patients experienced stability or improvements on metabolic parameters over 52 weeks of Acinetobacter baumannii-calcoaceticus complex. Our NDAtreatment. We are conducting a registrational bridging study in mainland China.
Corporate Updates
In April 2024, Andrew Zhu joined Zai Lab as our Chief Commercial Officer in Greater China. Mr. Zhu’s rich experience in building innovative business models and resource integration will help us further enhance our commercial operations and drive sales and profit growth across Greater China. He joins us from Simcere Zaiming, where he most recently served as Chief Operating Officer responsible for the treatmentcommercial and pharmaceutical business. He previously served in various operational, sales, and marketing leadership roles at leading global biopharmaceutical companies, including AstraZeneca, Roche, Sanofi, and BMS.
Factors Affecting Our Results of infections caused by Acinetobacter baumannii, including multidrug-resistantOperations
Our Commercial Products
We generate product revenue through the sale of our commercial products in Greater China, net of any related sales returns and carbapenem-resistant Acinetobacter baumannii strains, isrebates to distributors. Our cost of sales mainly consists of the costs of manufacturing ZEJULA and NUZYRA, costs of purchasing OPTUNE, QINLOCK, and VYVGART from our collaboration partners, any royalty fees incurred as a result of sales of our commercial products under review atour license and collaboration agreements, and amortization of any sales-based milestone fees incurred under our license and collaboration agreements. We expect our revenue to increase in coming years as we continue to focus on increasing patient access to our existing commercial products, such as through NRDL listing or increased supplemental insurance coverage in the NMPA and has been granted priority review status.private-pay market. For example, in the first quarter of
•KarXT (Xanomeline-Trospium, M1/M4-Preferring Muscarinic Agonist): In June 2023, we enrolledQINLOCK for fourth-line GIST and NUZYRA for the IV treatment of adult patients with CABP and ABSSSI were added to the NRDL. In the first patient in the registrational bridging study in mainland Chinaquarter of 2024, VYVGART (efgartigimod alfa injection) for KarXTgMG and NUZYRA for the oral treatment of adult patients with schizophrenia.
Corporate Updates
CABP and ABSSSI were added to the NRDL. We continuedalso expect revenue to enhance our portfolio through strategic partnerships and to strengthen our organizational structure to support the evolving needsincrease in coming years as a result of our business:
•Business Development: In April 2023,launch of additional commercial products, if and when we entered into a strategic partnership and global license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”). Through this collaboration, we expandedobtain required regulatory approvals. We expect our lung cancer franchise and global oncology pipeline with an early-stage next generation DLL3 ADC program, ZL-1310. DLL3 is an inhibitorcost of sales to increase as the Notch ligand that is overexpressed in small cell lung cancer and neuroendocrine tumors. ZL-1310 has demonstrated an encouraging pre-clinical profile. ZL-1310 is progressing to the clinical stage, and we plan to focus on advancing its global development.
•Organizational Update: The Company promoted Yajing Chen to Chief Financial Officer, effective July 7, 2023. Dr. Chen previously served as our Senior Vice President and Deputy Chief Financial Officer, helping to oversee finance, planning and forecasting, accounting, tax, treasury, and procurement matters since joining the Company in September 2021. She is a seasoned finance executive with more than 20 yearsvolume of experience in the life sciences industry as well as a Ph.D. trained scientist. She joined the Company from AstraZeneca where she held various roles of increasing responsibility from 2006 to 2021, including Chief Financial Officer for the U.S. Oncology Business Unit from 2019 to 2021 and Finance Controller of the Global Oncology Business Unit from 2016 to 2019. Her scientific background combined with her significant executive management experience, finance expertise at leading global companies, and business acumen provide a unique and valuable perspective to the Company and will help drive our next phase of growth. Dr. Chen succeeds Billy Cho, who stepped down from his role and left the Company on July 7, 2023.
Legal and Regulatory Developments
Our business has been and continues to be impacted by legal and regulatory developments in the jurisdictions in which we operate, particularly in mainland China where our operations and product markets are primarily located. In March 2023, the People’s Government of Hainan Province published revised Regulations for the Administration of the Imported Urgently Needed Drugs and Medical Devices in the Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone (the “BMTPZ”), which became effective in May 2023. Under these regulations, medical institutions in the BMTPZ meeting certain qualifications may apply to use our products that meet specified requirements, including drugs or medical devices that address specific urgent clinical needs that cannot be met with existing approved products. We have successfully used this pathway in the past, and with the revised regulation, we will continue to look for opportunities to use this pathway to accelerate our entry into the China market for product candidates in advance of NMPA approval. In July 2023, the Ministry of Science and Technology of the People’s Republic of China published an updated Service Guide for the Examination and Approval of Sampling, Collecting, Trading, Exporting Human Genetic Resources, which will impact the Company’s practices in filing for an advance approval with the HGRAC. In addition, in July 2023, a revised Counter-Espionage Law intended to strengthen provisions on the protection of national security in mainland China went into effect, which may increase our cyber security or operational costs and could subject us to investigative or enforcement actions by the Chinese government or regulatory authorities.
Factors Affecting Our Results of Operationssold increases.
Research and Development Expenses
We believe our ability to successfully develop product candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high quality product candidates requires a significant investment of resources over a prolonged period of time,time. We are committed to advancing and expanding our pipeline of potential best-in-class and first-in-class products, such as through clinical and pre-clinical trials and business development activities. As a core part of our strategy isresult, we expect to continue making sustainedsignificant investments in research and development, including internal discovery activities. As a result
Elements of this commitment, our pipeline of product candidates has been advancing and expanding, with thirteen late-stage clinical product candidates being investigated as of June 30, 2023.
We have financed our activities primarily through private placements, our initial public offering in September 2017 and multiple follow-on offerings on Nasdaq and our secondary listing and initial public offering on the Hong Kong Stock Exchange in September 2020. Through June 30, 2023, we have raised approximately $164.6 million from private equity financing and approximately $2,462.7 million in net proceeds after deducting underwriting commissions and the offering expenses payable by us from our initial public offerings and follow-on offerings. Our operations have consumed substantial amounts of cash since inception. The net cash used in our operating activities was $128.0 million and $132.0 million for the six months ended June 30, 2023 and 2022, respectively. We expect our expenditures to increase in connection with our ongoing activities, particularly as we advance the clinical development of our thirteen late-stage clinical product candidates, research and develop our clinical- and pre-clinical-stage product candidates, and initiate additional clinical trials of, and seek regulatory approval for, these and other future product candidates. Thesedevelopment expenditures primarily include:
•expenses incurred forpayroll and other related costs of personnel engaged in research and development activities;
•in-licensed patent rights fees of exclusive development rights of products granted to the Company;
•costs related to pre-clinical testing of the Company’s technologies and clinical trials, such as payments to contract research organizations (“CROs”), and contract manufacturemanufacturing organizations (“CMOs”), investigators, and clinical trial sites that conduct our clinical studies;
•employee compensation related expenses, including salaries, benefits, and equity compensation expenses;
•expenses for licensors;
•the cost of acquiring, developing, and manufacturing clinical study materials;
•facilities and other expenses, which include office leases and other overhead expenses;
•costs associated with pre-clinical activitiesto produce the product candidates, including raw materials and regulatory operations;supplies, product testing, depreciation, and
•expenses associated with the construction and maintenance of our manufacturing facilities. facility-related expenses.
Selling, General, and Administrative Expenses
Our selling, general, and administrative expenses consist primarily of personnel compensation and related costs, including share-based compensation for commercial and administrative personnel. Other selling, general, and administrative expenses include product distribution and promotion costs, and professional service fees for legal, intellectual property, consulting, auditing, and tax services as well as other direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies used in selling, general, and administrative activities. We anticipate that our selling, general, and administrative expenses will increase in future periodsexpect these costs to continue to be significant to support increases insales of our commercial and research and development activities and as we continue to discover, develop, commercialize, and manufacture our products and preparation to launch and subsequent sales of additional product candidates. These increases will likely include expanded infrastructure as well as increased headcount,candidates if and share-based compensation, product distribution, promotion, and insurance costs. We also anticipate incurring additional legal, compliance, accounting, and investor and public relations expenses associated with being a public company listed on both Nasdaq and the Hong Kong Stock Exchange.when approved.
Our Ability to Commercialize Our Product Candidates
As of August 1, 2023, thirteen of ourWe have multiple product candidates are in late-stage clinical development and various others are in clinical and pre-clinical development in Greater China and the United States. Our ability to generate revenue from our product candidates is dependent on our receipt of regulatory approvals for and successful commercialization of such product candidates, which may not occur. Certain of our product candidates may require additional pre-clinical and/or clinical development, regulatory approvals in multiple jurisdictions, manufacturing supply, substantial investment, and significant marketing efforts before we generate any revenue from product sales.
License and Collaboration Arrangements
Our results of operations have been, and we expect them towill continue to be, affected by our license and collaboration agreements. We areIn accordance with these agreements, we may be required to make upfront payments upon our entry into such agreements and milestone payments upon the achievement of certain development, regulatory, and sales-based milestones for the relevant products under these agreements as well as certain royalties at tiered percentage rates based on annual net sales of the licensed products. We recorded research and development expense related to upfront license fees and development milestonesproducts in the licensed territories. As of $18.3 million and $19.3 million for the three and six months ended June 30, 2023, respectively, and $10.4 million for both the three and six months ended June 30, 2022. WeMarch 31, 2024, we may be obligatedrequired to pay development and regulatory milestone payments of up to an additional aggregate amount of approximately $2,443.8$303.5 million in developmentfor our current clinical programs and regulatory milestone payments and $3,437.4$665.2 million in sales-based milestone paymentsfor other programs that are contingent on the progress of our product performancecandidates prior to commercialization. As of March 31, 2024, we also may be
required to pay sales-based milestone payments of up to an additional aggregate amount of $2,457.5 million as well as certain royalties at tiered percentage rates on annual net sales. These milestones may occur before the Company has commercialized or received any revenue from the licensedsales that are contingent on product or they may not occur at all.performance. If these milestones or royalties do occur, we view related payments as positivefavorable because theysuch payments signify that the product or product candidate is achieving higher sales levels or advancing toward potential commercial launch or achieving higher sales levels.
The COVID-19 Pandemic
Our results of operations have been adversely affected by the COVID-19 pandemic, including by government actions and quarantine measures taken in response in 2022 and increased infection rates in the first quarter of 2023 after COVID restrictions were lifted or eased, particularly in mainland China where our operations and product markets are primarily located. The COVID-19 pandemic did not have a material adverse effect on our business or results of operations in the second quarter of 2023.launch.
Results of Operations
The following table presents our results of operations ($ in thousands):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended June 30, | | Change | | Six Months Ended June 30, | | Change |
| | 2023 | | 2022 | | $ | | % | | 2023 | | 2022 | | $ | | % |
| Revenues: | | | | | | | | | | | | | | | | |
| Product revenue, net | | 68,864 | | | 47,575 | | | 21,289 | | | 45 | % | | 131,661 | | | 93,670 | | | 37,991 | | | 41 | % |
| Collaboration revenue | | — | | | 601 | | | (601) | | | (100) | % | | — | | | 1,230 | | | (1,230) | | | (100) | % |
| Total revenues | | 68,864 | | | 48,176 | | | 20,688 | | | 43 | % | | 131,661 | | | 94,900 | | | 36,761 | | | 39 | % |
| Expenses: | | | | | | | | | | | | | | | | |
| Cost of sales | | (23,763) | | | (17,407) | | | (6,356) | | | 37 | % | | (45,100) | | | (33,051) | | | (12,049) | | | 36 | % |
| Research and development | | (76,682) | | | (66,084) | | | (10,598) | | | 16 | % | | (125,153) | | | (119,938) | | | (5,215) | | | 4 | % |
| Selling, general, and administrative | | (67,920) | | | (63,401) | | | (4,519) | | | 7 | % | | (130,430) | | | (120,392) | | | (10,038) | | | 8 | % |
| Gain on sale of intellectual property | | 10,000 | | | — | | | 10,000 | | | NM | | 10,000 | | | — | | | 10,000 | | | NM |
| Loss from operations | | (89,501) | | | (98,716) | | | 9,215 | | | (9) | % | | (159,022) | | | (178,481) | | | 19,459 | | | (11) | % |
| Interest income | | 10,090 | | | 1,175 | | | 8,915 | | | 759 | % | | 20,321 | | | 1,363 | | | 18,958 | | | 1391 | % |
| Foreign currency loss | | (40,079) | | | (34,895) | | | (5,184) | | | 15 | % | | (31,167) | | | (32,610) | | | 1,443 | | | (4) | % |
| Other expense, net | | (1,405) | | | (5,497) | | | 4,092 | | | (74) | % | | (171) | | | (10,378) | | | 10,207 | | | (98) | % |
| Loss before income tax and share of loss from equity method investment | | (120,895) | | | (137,933) | | | 17,038 | | | (12) | % | | (170,039) | | | (220,106) | | | 50,067 | | | (23) | % |
| Income tax expense | | — | | | — | | | — | | | — | % | | — | | | — | | | — | | | — | % |
| Share of loss from equity method investment | | — | | | — | | | — | | | — | % | | — | | | (221) | | | 221 | | | (100) | % |
| Net loss | | (120,895) | | | (137,933) | | | 17,038 | | | (12) | % | | (170,039) | | | (220,327) | | | 50,288 | | | (23) | % |
| Net loss attributable to ordinary shareholders | | (120,895) | | | (137,933) | | | 17,038 | | | (12) | % | | (170,039) | | | (220,327) | | | 50,288 | | | (23) | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | Three Months Ended March 31, | | Change | | | | |
| | 2024 | | 2023 | | $ | | % | | | | | | | | |
| Revenue | | 87,149 | | | 62,797 | | | 24,352 | | | 39 | % | | | | | | | | |
| Expenses | | | | | | | | | | | | | | | | |
| Cost of sales | | (33,619) | | | (21,337) | | | (12,282) | | | 58 | % | | | | | | | | |
| Research and development | | (54,645) | | | (48,472) | | | (6,173) | | | 13 | % | | | | | | | | |
| Selling, general, and administrative | | (69,194) | | | (62,510) | | | (6,684) | | | 11 | % | | | | | | | | |
| Loss from operations | | (70,309) | | | (69,522) | | | (787) | | | 1 | % | | | | | | | | |
| Interest income | | 9,658 | | | 10,232 | | | (574) | | | (6) | % | | | | | | | | |
| Interest expenses | | (113) | | | — | | | (113) | | | NM | | | | | | | | |
| Foreign currency (losses) gains | | (2,068) | | | 8,912 | | | (10,980) | | | (123) | % | | | | | | | | |
| Other income, net | | 9,361 | | | 1,234 | | | 8,127 | | | 659 | % | | | | | | | | |
| Loss before income tax | | (53,471) | | | (49,144) | | | (4,327) | | | 9 | % | | | | | | | | |
| Income tax expense | | — | | | — | | | — | | | — | % | | | | | | | | |
| Net loss | | (53,471) | | | (49,144) | | | (4,327) | | | 9 | % | | | | | | | | |
NM - Not Meaningful
Revenues
Product Revenue
The following table presents the components of the Company’s product revenue ($ in thousands):
| | Three Months Ended June 30, | | Change | | Six Months Ended June 30, | | Change |
| 2023 | | 2022 | | $ | | % | | 2023 | | 2022 | | $ | | % |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | 2024 | |
| | 2024 | |
| | 2024 | |
| Product revenue - gross | Product revenue - gross | | 75,010 | | | 54,339 | | | 20,671 | | | 38 | % | | 146,222 | | | 107,649 | | | 38,573 | | | 36 | % |
| Less: Rebates and sales return | | (6,146) | | | (6,764) | | | 618 | | | (9) | % | | (14,561) | | | (13,979) | | | (582) | | | 4 | % |
| Product revenue - gross | |
| Product revenue - gross | |
| Less: Rebates and sales returns | |
| Less: Rebates and sales returns | |
| Less: Rebates and sales returns | |
| Product revenue - net | Product revenue - net | | 68,864 | | | 47,575 | | | 21,289 | | | 45 | % | | 131,661 | | | 93,670 | | | 37,991 | | | 41 | % |
| Product revenue - net | |
| Product revenue - net | |
Our product revenue is primarily derived from the sales of ZEJULA, Optune, QINLOCK, and NUZYRAour commercial products primarily in mainland China, and Hong Kong, net of sales returns and rebates to distributors in mainland China with respect to the sales of these products. We had a minimal amount of revenue for VYVGART from our named patient program in mainland China in the second quarter of 2023.
Our net product revenue increased by $21.3 million and $38.0$24.4 million in the three and six months ended June 30, 2023, respectively,first quarter of 2024 primarily driven by increased sales volumes, the launch of VYVGART, and decreased negative effectssales rebates to distributors resulting from the COVID-19 pandemic. The adverse effectsprice reductions in connection with NRDL listings for certain products. In terms of the COVID-19 pandemic hadrevenue growth by product, ZEJULA, which was renewed with NRDL as a more significant impact on our sales volumes for the three and six months ended June 30, 2022 andmaintenance treatment in the first quarter of 2024, continued being the leading PARP inhibitor in hospital sales for ovarian cancer in mainland China; VYVGART for gMG was commercially launched in mainland China in September 2023 due to decreased patient access to our products, such as through reduced hospital access during periods of lockdown or high infection rates, fewer newly diagnosed oncology patients, and delayed or interrupted treatments. The COVID-19 pandemic did not have a material adverse effect on our sales volumewas included in the secondNRDL in the first quarter of 2023.
For the three and six months ended June 30, 2023, our product revenue included negative adjustments of $1.3 million and $5.2 million, respectively, to compensate distributors2024; increased sales for sales of QINLOCK and NUZYRA at prices prior to the price reductions made in connection with their addition to the NRDL. The Company lowered the selling price of ZEJULA due towere supported by its inclusion in the NRDL in December 2021the first quarter of 2023; and increased sales for certain therapies. In June 2022,NUZYRA were supported by the Company loweredinclusion in the selling priceNRDL for QINLOCKits IV formulation in the first quarter of 2023 and NUZYRA. Accordingly, for its oral formulation in the three and six months ended June 30, 2022, our productfirst quarter of 2024. Although revenue included negative adjustments of $3.2 million and $5.8 million, respectively, to compensate distributorsdeclined for sales of ZEJULA, QINLOCK and NUZYRA at prices priorOPTUNE, it increased compared to the price reductions. Suchfourth quarter of 2023 as patient volume recovered.
In the first quarter of 2023, our sales rebates to distributors on previously purchased products are customaryresulting from price reductions in our industry to compensate those distributorsconnection with NRDL listings was $3.9 million, which was driven by price reductions for QINLOCK and NUZYRA in connection with their NRDL listings in the new NRDL selling price.first quarter of 2023. Such sales rebates were immaterial in the first quarter of 2024.
The following table presents net revenue by product ($ in thousands):
| | Three Months Ended June 30, | | Change | | Six Months Ended June 30, | | Change |
| 2023 | | 2022 | | $ | | % | | 2023 | | 2022 | | $ | | % |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | 2024 | |
| | 2024 | |
| | 2024 | |
| ZEJULA | ZEJULA | | 42,957 | | | 34,052 | | | 8,905 | | | 26 | % | | 85,637 | | | 63,649 | | | 21,988 | | | 35 | % |
| Optune | | 13,692 | | | 11,592 | | | 2,100 | | | 18 | % | | 27,034 | | | 24,389 | | | 2,645 | | | 11 | % |
| ZEJULA | |
| ZEJULA | |
| OPTUNE | |
| OPTUNE | |
| OPTUNE | |
| QINLOCK | |
| QINLOCK | |
| QINLOCK | QINLOCK | | 7,527 | | | 623 | | | 6,904 | | | 1108 | % | | 8,833 | | | 3,582 | | | 5,251 | | | 147 | % |
| NUZYRA | NUZYRA | | 4,636 | | | 1,308 | | | 3,328 | | | 254 | % | | 10,105 | | | 2,050 | | | 8,055 | | | 393 | % |
| NUZYRA | |
| NUZYRA | |
| VYVGART | |
| VYVGART | |
| VYVGART | VYVGART | | 52 | | | — | | | 52 | | | NM | | 52 | | | — | | | 52 | | | NM |
| Total product revenue, net | Total product revenue, net | | 68,864 | | | 47,575 | | | 21,289 | | | 45 | % | | 131,661 | | | 93,670 | | | 37,991 | | | 41 | % |
| Total product revenue, net | |
| Total product revenue, net | |
NM - Not Meaningful
Cost of Sales
Cost of sales increased by $6.4$12.3 million and $12.0to $33.6 million in the three and six months ended June 30, 2023, respectively. These increases werefirst quarter of 2024, primarily due to increasing sales volumes and higher royalties.
shifts in product sales mix.Research and Development Expenses
The following table presents the components of our research and development expenses ($ in thousands):
| | | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | 2024 | |
| | 2024 | |
| | 2024 | |
| | Three Months Ended June 30, | | Change | | Six Months Ended June 30, | | Change |
| Personnel compensation and related costs | |
| | 2023 | | 2022 | | $ | | % | | 2023 | | 2022 | | $ | | % |
| Personnel compensation and related costs | |
| | Personnel compensation and related costs | Personnel compensation and related costs | | 29,378 | | | 27,045 | | | 2,333 | | | 9 | % | | 58,034 | | | 51,847 | | | 6,187 | | | 12 | % |
| Licensing fees | Licensing fees | | 18,282 | | | 10,436 | | | 7,846 | | | 75 | % | | 19,282 | | | 10,436 | | | 8,846 | | | 85 | % |
| Licensing fees | |
| Licensing fees | |
| CROs/CMOs/Investigators expenses | |
| CROs/CMOs/Investigators expenses | |
| CROs/CMOs/Investigators expenses | CROs/CMOs/Investigators expenses | | 23,626 | | | 23,368 | | | 258 | | | 1 | % | | 36,065 | | | 46,918 | | | (10,853) | | | (23) | % |
| Other costs | Other costs | | 5,396 | | | 5,235 | | | 161 | | | 3 | % | | 11,772 | | | 10,737 | | | 1,035 | | | 10 | % |
| Other costs | |
| Other costs | |
| Total | Total | | 76,682 | | | 66,084 | | | 10,598 | | | 16 | % | | 125,153 | | | 119,938 | | | 5,215 | | | 4 | % |
| Total | |
| Total | |
Research and development expenses increased by $10.6 million and $5.2$6.2 million in the three and six months ended June 30, 2023, respectively,first quarter of 2024, primarily due to:
•an increase of $7.8$7.5 million in CROs/CMOs/Investigators expenses related to newly initiated studies and $8.8progress of existing studies; partially offset by
•a decrease of $1.0 million respectively, in licensing fees in connection with increased upfront anddecreased development milestone paymentsfees for our license and collaboration agreements;
•an increase of $2.3 million and $6.2 million, respectively, in personnel compensation and related costs primarily due to headcount growth and grants of share options and restricted shares and the continued vesting of option and restricted share awards; and
•an increase of $0.3 million and $1.0 million, respectively, in CROs/CMOs/Investigators expenses related to ongoing and newly initiated clinical trials.
The increase in research and development expenses in the six months ended June 30, 2023 was partially offset by a decrease of $10.9 million in CROs/CMOs/Investigators expenses due to compensation from collaboration partners related to our clinical trials.agreements.
The following table presents our research and development expenses by program ($ in thousands):
| | Three Months Ended June 30, | | Change | | Six Months Ended June 30, | | Change |
| 2023 | | 2022 | | $ | | % | | 2023 | | 2022 | | $ | | % |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | 2024 | |
| | 2024 | |
| | 2024 | |
| Clinical programs | |
| Clinical programs | |
| Clinical programs | Clinical programs | | 32,462 | | | 33,292 | | | (830) | | | (2) | % | | 44,989 | | | 56,144 | | | (11,155) | | | (20) | % |
| Pre-clinical programs | Pre-clinical programs | | 10,758 | | | 1,957 | | | 8,801 | | | 450 | % | | 13,239 | | | 4,522 | | | 8,717 | | | 193 | % |
| Pre-clinical programs | |
| Pre-clinical programs | |
| Unallocated research and development expenses | |
| Unallocated research and development expenses | |
| Unallocated research and development expenses | Unallocated research and development expenses | | 33,462 | | | 30,835 | | | 2,627 | | | 9 | % | | 66,925 | | | 59,272 | | | 7,653 | | | 13 | % |
| Total | Total | | 76,682 | | | 66,084 | | | 10,598 | | | 16 | % | | 125,153 | | | 119,938 | | | 5,215 | | | 4 | % |
| Total | |
| Total | |
Research and development expenses attributable to clinical programs remained relatively flat during the three months ended June 30, 2023. Research and development expenses attributable to clinical programs decreasedincreased by $11.2$6.3 million in the six months ended June 30, 2023,first quarter of 2024 primarily driven by compensation from collaboration partnersincreased CROs/CMOs/Investigators expenses related to our clinical trials in the three months ended March 31, 2023.newly initiated studies and progress of
existing studies. Research and development expenses attributable to pre-clinical programs increaseddecreased by $8.8 million and $8.7$0.4 million in the threefirst quarter of 2024 primarily due to a decrease in milestone fees for our license and six months ended June 30, 2023, respectively, primarily driven by increased license fees.collaboration agreements.
Although we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any given time.
Selling, General, and Administrative Expenses
The following table presents our selling, general and administrative expenses by program ($ in thousands):
| | Three Months Ended June 30, | | Change | | Six Months Ended June 30, | | Change |
| 2023 | | 2022 | | $ | | % | | 2023 | | 2022 | | $ | | % |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | Three Months Ended March 31, | |
| | 2024 | |
| | 2024 | |
| | 2024 | |
| Personnel compensation and related costs | |
| Personnel compensation and related costs | |
| Personnel compensation and related costs | Personnel compensation and related costs | | 42,874 | | | 41,320 | | | 1,554 | | | 4 | % | | 83,788 | | | 79,523 | | | 4,265 | | | 5 | % |
| Professional service fees | Professional service fees | | 5,793 | | | 8,072 | | | (2,279) | | | (28) | % | | 14,348 | | | 15,505 | | | (1,157) | | | (7) | % |
| Professional service fees | |
| Professional service fees | |
| Other costs | |
| Other costs | |
| Other costs | Other costs | | 19,253 | | | 14,009 | | | 5,244 | | | 37 | % | | 32,294 | | | 25,364 | | | 6,930 | | | 27 | % |
| Total | Total | | 67,920 | | | 63,401 | | | 4,519 | | | 7 | % | | 130,430 | | | 120,392 | | | 10,038 | | | 8 | % |
| Total | |
| Total | |
Selling, general, and administrative expenses increased by $4.5 million and $10.0$6.7 million in the three and six months ended June 30, 2023, respectively,first quarter of 2024, primarily due to:
•an increase of $5.2$6.2 million and $6.9 million, respectively, in other costs, mainly related to higher general selling rental, and administrative expenses for commercial operationsVYVGART which was launched in mainland China, Hong Kong,September 2023 and Taiwan; andhigher promotional fees for NUZYRA due to increased sales.
•an increase of $1.6$5.0 million and $4.3 million, respectively, in personnel compensation and related costs which was primarily driven by headcount growth, particularly in commercial and administrative personnel, and grants of share options and restricted shares and the continued vesting of option and restricted share awards; those increases weregrowth; partially offset by
•a decrease of $2.3$4.5 million and $1.2 million, respectively, in professional service fees, primarily related to legal, compliance, accounting, human resources administrative, and commercial expenses.
Gain on Sale of Intellectual Property
During the second quarter of 2023, we sold certain patent rights and related know-how to a third party, resulting in a gain of $10.0 million in the three and six months ended June 30, 2023. We had no such intellectual property sales resulting in gains or losses in the prior year periods.
Interest Income
Interest income increaseddecreased by $8.9$0.6 million and $19.0to $9.7 million in the three and six months ended June 30, 2023, respectively,first quarter of 2024 primarily due to decreased cash and cash equivalents.
Interest Expenses
Interest expenses increased by $0.1 million in the first quarter of 2024 primarily due to interest rates.expenses on short-term debts we entered into in February 2024. We had no such interest expenses in the prior year period.
Foreign Currency Loss(Losses) Gains
Foreign currency loss increased by $5.2losses was $2.1 million in the three months ended June 30, 2023,first quarter of 2024, primarily driven by increased remeasurement loss due to depreciation of the Renminbi (“RMB”) against the U.S. dollar.
Foreign currency loss decreased by $1.4 million in the six months ended June 30, 2023, primarily driven by decreased remeasurement losslosses due to depreciation of the RMB against the U.S. dollar.
Other Expenses, Net
Other expenses, net decreased by $4.1dollar, compared to foreign currency gain of $8.9 million in the three months ended June 30,first quarter of 2023, driven by remeasurement gain due to appreciation of the RMB against the U.S. dollar.
Other Income, Net
Other income, net increased by $8.1 million to $9.4 million in the first quarter of 2024, primarily due to an increase of $4.4 million in gain of our equity investment in MacroGenics, Inc as a result of a decreasechanges in equity investment loss in MacroGenicsits stock price and an increase of $3.9 million.
Other expenses, net decreased by $10.2$2.8 million in the six months ended June 30, 2023 primarily as a result of a decrease in equity investment loss in MacroGenics of $11.3 million, partially offset by a decrease in governmental subsidies of $1.5 million.government grants.
Income Tax Expense
There was no change in our incomeIncome tax expense which was zeronil in the threefirst quarter of 2024 and six months ended June 30, 2023 and 2022.2023.
Net Loss
Net loss was $53.5 million in the first quarter of 2024, or a loss per ordinary share attributable to common stockholders of $0.05 (or loss per ADS of $0.55), compared to a net loss of $49.1 million in the first quarter of 2023, or a loss per ordinary share of $0.05 (or loss per ADS of $0.51).
Critical Accounting Policies and Significant Judgments and Estimates
We prepare our financial statements in conformity with U.S. GAAP, which requires usmanagement to make judgments, estimates, and assumptions. We periodically evaluate these judgments, estimates, and assumptions based on the most recently available information, our own historical experiences, and various other assumptions that we believe toaffect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. Some of those judgments can be reasonable under the circumstances. Since the use of estimates is an integral component of the financial reporting process, actualsubjective and complex. Actual results could differ from our expectations as a result of changes in our estimates. Some of our accounting policies require a higher degree of judgment than others in their application and require us to make significant accounting estimates.
The selection ofOur most critical accounting policies and estimates, including those that require the most difficult, subjective, or complex judgments and other uncertainties affecting application of those policies, and the sensitivity of reported results to changes in conditions and assumptions are factors that should be considered when reviewing our financial statements. We believe the following accounting policies involve the most significant judgments and estimates used in the preparation of our financial statements.inherently uncertain, are described below.
Revenue Recognition
Description
In mainland China, weWe sell our products to distributors (our customers), who ultimately sell the products to healthcare providers. Based on the nature of the arrangements,providers, primarily in mainland China. We recognize revenue when the performance obligations are satisfied upon the product’s delivery to distributors.
Judgments and Uncertainties
Rebates are offeredWe offer rebates to our distributors to compensate the distributors consistent with pharmaceutical industry practices. We are required to establish a provision for rebates in the same period the related product sales are recognized. The estimated amount of unpaid or unbilled rebates, if any, is recorded as a reduction of revenue. We estimate rebates based on
Significant judgments are required in making these estimates. In determining the appropriate accrual amount, we consider our contracted rates, sales volumes, and levellevels of distributor inventories.
Sensitivity of Estimate to Change
Actual amounts of rebates paid or billed may differ from our estimates. We regularly review the factorsinventories, and judgments underlying these estimateshistorical experiences and adjust the amounts of rebates accordingly.trends. If actual results vary from our estimates or our expectations change, we alsowill adjust these estimates accordingly, which would affect net product revenue and earnings in the period such variances become expected or known.
Research and Development Expenses
Description
ResearchWe have a significant amount of research and development expenses, including with respect to pre-clinical and clinical trials for our product candidates. Such costs are charged to expenseexpensed as incurred when these expenditures relate to our research and development services andthey have no alternative future uses.
Pre-clinical and clinical trial costs are a significant component of our research and development expenses. We have a history of contractingcontract with third parties thatto perform various pre-clinical and clinical trial activities on our behalf in the ongoing development of our product candidates. Expenses related to pre-clinical and clinical trialstrial activities are accrued based on ourthe Company’s estimates of the actual services performed by the third parties, such as CROs and CMOs.
Significant judgments are required in estimating the actual services performed by the third parties for the respective period.
Judgments and Uncertainties
The process of estimating our research and development expenses involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performedperiod and the associated costs incurred forrelated expense accruals. In determining the appropriate accrual, we consider a variety of factors, including contractual requirements with respect to services to be provided, related rates, and our assessment of services performed during the period and progress with respect to any contractual milestones when we have not yet been invoiced or otherwise notified by third parties of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule, or when contractual milestones are met; however, some require advanced payments. We make estimates of our research and development expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time.
Sensitivity of Estimate to Change
Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative toIf the actual status and timing of services performed vary from our estimates, our reported expenses and earnings for the corresponding period may be affected.
Share-Based Compensation
We grant share-based awards, including share options and restricted shares, to eligible employees, non-employees, and directors. Such share-based awards are measured at grant date fair value.
may vary and may resultSignificant assumptions are required in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.
Share-Based Compensation
Description
Share-based awards for our employees are measured at grant date fair value and recognized as expenses (1) immediately at grant date if no vesting conditions are required; or (2) using a straight-line method over the requisite service period, which is the vesting period.
To the extent the required vesting conditions are not met resulting in forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed.
Judgments and Uncertainties
We determinedetermining the fair value of stockshare options, granted to employeeswhich we estimate using the Black-Scholes option valuation model. Using this model, fair value is calculated based onThese assumptions with respect toinclude: (i) the expected volatility of our ADS price, (ii) the periods of time over which grantees are expected to hold their options prior to exercise (expected lives)term), (iii) the expected dividend yield on our ADSs, and (iv) risk-free interest rates, which arerates. Since we do not have sufficient trading history since our September 2017 initial public offering on Nasdaq to cover the expected term of our share options, we estimate expected volatility based on quoted U.S. Treasury rates for securities with maturities approximating the expected lives of the options. Expected volatility has been estimated based on actual movements in somethe share price of certain companies we consider comparable companies’ stock price over the most recent equivalent historical periods equivalent to the options’ expected lives. The expected term of the share options represents the average period the share options are expected to remain outstanding. As the Company doesperiod. Since we do not have sufficient historical information since its IPO to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term of options granted is derived from the average midpoint between the weighted average vesting and the contractual term, also known as the simplified method. The expected dividend yield is zero as we have never paid dividends and do not currently anticipate paying any in the foreseeable future.
Sensitivity of Estimate to Change
The assumptions used in this method to determinefuture, and risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the fair value ofexpected term. If actual results vary from our option shares consider historical trends, macroeconomic conditions,estimates or our expectations change, our reported expenses and projections consistent withearnings for the Company’s operating strategy. Changes in these estimates can have a significant impact on the determination of fair value of the option shares. If factors change or different assumptions are used, our share-based compensation expenses couldcorresponding period may be materially different for any period.affected.
Income Taxes
Description
InWe recognize deferred tax assets and liabilities for temporary differences between the financial statement and income tax bases of assets and liabilities, which are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some or all of a deferred tax asset will not be realized. Significant judgements are required when evaluating tax positions in accordance with the provisions of ASC 740, Income Taxes we.
We recognize in our financial statements the benefit of a tax position if the tax position is “more likely than not” to prevail based on the facts and technical merits of the position. Tax positions that meet the “more likely than not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. We estimate our liability for unrecognized tax benefits which are periodically assessed and may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and the expiration of the applicable statute of limitations. The ultimate outcome for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in some cases, appeal or litigation process.
Judgments and Uncertainties
We consider positive and negative evidence when determining whether some portion or all of our deferred tax assets will not be realized. This assessment considers among other matters,various factors, including the nature, frequency, and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, our historical results of operations, and our tax planning strategies. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based uponOur estimates may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and expiration of the levelstatute of our historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, we believe it is more likely than not that we will not realize the deferred tax assets resulted from the tax loss carried forward in the future periods.
Sensitivity of Estimate to Change
Thelimitations. If actual benefits ultimately realized may differvary from our estimates. As each audit is concluded, adjustments, if any, are recorded inestimates or our financial statements in the period in which the audit is concluded. Additionally, in future periods, changes in facts and circumstances and new information may require us toexpectations change, we will adjust the recognition and measurement estimates with regard to individual tax positions. Changes in recognitionaccordingly, which would affect reported expenses and measurement estimates are recognizedearnings in the period in which the changes occur. As of June 30, 2023 and 2022, we did not have any significant unrecognized uncertain tax positions.corresponding period.
Liquidity and Capital Resources
To date, we have financed our activities primarily through private placements, our September 2017 initial public offering and various follow-on offerings on Nasdaq, and our September 2020 secondary listing and initial public offering on the Hong Kong Stock Exchange. Through June 30, 2023,In addition, we have raised approximately $164.6 million in private equity financing and approximately $2,462.7 million in net proceeds after deducting underwriting commissions and the offering expenses payable by us in our initial public offering and subsequent follow-on offerings on Nasdaq and our initial public offering on the Hong Kong Stock Exchange. Our operations have consumed substantial amounts of cash since inception. The net cash used in our operating activities was $128.0$90.1 million and $132.0$69.3 million forin the six months ended June 30,first quarter of 2024 and 2023, and 2022, respectively. As of June 30, 2023, we had commitments for capital expenditures of $3.9 million, mainly for the purpose of plant construction and installation. For information on our research and development activities and related expenditures see the Research and Development Expenses, Selling, General, and Administrative Expenses, License and Collaboration Arrangements, and Results of Operations sections in MD&A above. In addition, as of March 31, 2024, we had commitments for capital expenditures of $1.1 million, mainly for the purpose of plant construction and installation.
As of June 30, 2023,March 31, 2024, we had cash and cash equivalents, current restricted cash, and short-term investments of $876.4 million. Based on our current operating plan,$750.8 million, which we expect that our cash, cash equivalents, restricted cash, and short-term investments, will enable us to meet our cash requirements and fund ourincluding the funding of operating expenses, capital expenditures, and capital expenditure requirementsdebt obligations for at least the next 12 months. However,
Although we believe that we have sufficient capital to fund our operations for at least the next twelve months, we may, from time to time, identify opportunities to access capital through debt arrangements on favorable commercial terms. In February 2024, we entered into three such debt arrangements with Chinese financial institutions that allow certain of our subsidiaries to borrow up to approximately $164.5 million (or RMB1,171.7 million) to support our working capital needs in ordermainland China. As of March 31, 2024, we have short-term debts of approximately $48.3 million (or RMB342.5 million) pursuant to bringthese debt arrangements. These debt arrangements will provide us with additional capital capacity that gives us enhanced flexibility to fruitionexecute on our research and development objectives,corporate strategic goals. For more information, see Note 9.
We may consider, or we may ultimately need, additional funding sources to bring to fruition or research and development objectives or otherwise, and there can be no assurances that such funding will be made available to us on acceptable terms or at all.
The following table presents information regarding our cash flows ($ in thousands):
| | Six Months Ended
June 30, | | Change |
| 2023 | | 2022 | | $ |
| | Three Months Ended
March 31, | | | | Three Months Ended
March 31, | | Change |
| | 2024 | | | | 2024 | | 2023 | | $ |
| Net cash used in operating activities | Net cash used in operating activities | | (127,989) | | | (132,027) | | | 4,038 | |
| Net cash used in investing activities | | (11,252) | | | (143,869) | | | 132,617 | |
| Net cash used in financing activities | | (5,379) | | | (2,240) | | | (3,139) | |
| Net cash provided by (used in) investing activities | |
| Net cash provided by (used in) financing activities | |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | | (3,707) | | | (5,144) | | | 1,437 | |
| Net decrease in cash, cash equivalents and restricted cash | Net decrease in cash, cash equivalents and restricted cash | | (148,327) | | | (283,280) | | | 134,953 | |
Net Cash Used in Operating Activities
Net cash used in operating activities decreasedincreased by $4.0$20.8 million to $128.0$90.1 million in the six months ended June 30, 2023,first quarter of 2024, primarily due to a decreasean increase of $50.3$24.7 million in net changes in operating assets and liabilities, an increase of $4.3 million in net loss, partially offset by a decrease of $35.2 million in net changes in operating assets and liabilities and a decrease of $11.1$8.3 million in adjustments to reconcile net loss to net cash used in operating activities.
Net Cash Used inProvided by (Used in) Investing Activities
Net cash provided by investing activities was $3.3 million in the first quarter of 2024, compared to net cash used in investing activities decreased by $132.6 million to $11.3 millionof $54.0 in the six months ended June 30,first quarter of 2023. The decreaseThis shift was primarily due to a decrease of $160.3$100.0 million in purchases of short-term investments, an increase
of $10.0 million in proceeds from sale of intellectual property, and a decrease of $8.3$2.5 million in purchases of property and equipment, partially offset by a decrease of $45.5$33.2 million in proceeds from the maturity of short-term investments.investments, and an increase of $12.0 million from acquisition of intangible assets as we made a sales-based milestone payment which was capitalized as intangible assets in the fourth quarter of 2023.
Net Cash Used inProvided by (Used in) Financing Activities
Net cash provided by financing activities was $47.5 million in the first quarter of 2024, compared to net cash used in financing activities increased by $3.1 million to $5.4of $3.9 million in the six months ended June 30, 2023,first quarter of 2023. This shift was primarily due to a decrease$48.2 million in proceeds from short-term debts we entered into in the first quarter of $2.92024, partially offset by decreases of $5.1 million in taxes paid related to settlement of equity awards and $1.2 million in proceeds from exercises of stock options and an increase of $0.3 million in employee taxes paid related to net share settlement of equity awards.options.
Recently Issued Accounting Standards
For more information regarding recently issued accounting standards, see Part II – Item 8. Financial Statements and Supplementary Data – Recent Accounting Pronouncements in our 20222023 Annual Report. The Company has not adopted any new accounting standards since December 31, 2022.2023.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to market risk including foreign exchange risk credit risk, and inflationcredit risk.
Foreign Exchange Risk
Renminbi, or RMB, is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People’s Bank of China (“PBOC”), controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The cash and cash equivalents of the Company included aggregated amounts of RMB158.7$17.9 million and RMB316.8$25.1 million, which were denominated in RMB, representing 3% and 5% of the cash and cash equivalents as of June 30, 2023both March 31, 2024 and December 31, 2022,2023, respectively.
While our financial statements are presented in U.S. dollars, our business mainly operates in mainland China with a significant portion of our transactions settled in RMB, and as such, we do not believe that we currently have significant direct foreign exchange risk and have not used derivative financial instruments to hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in our ADSs and ordinary shares will be affected by the exchange rate between the U.S. dollar and the RMB and between the HK dollar and the RMB, respectively, because the value of our business is effectively denominated in RMB, while ADSs and ordinary shares are traded in U.S. dollars and HK dollars, respectively.
The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in Greater China’s political and economic conditions. The conversion of RMB into foreign currencies, including U.S. dollars, has been based on rates set by the PBOC. On July 21, 2005, the Chinese government changed its decade-old policy of pegging the value of the RMB to the U.S. dollar. Under the revised policy, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. This change in policy resulted in a more than 20% appreciation of the RMB against the U.S. dollar in the following three years. Between July 2008 and June 2010, this appreciation halted, and the exchange rate between the RMB and U.S. dollar remained within a narrow band. In June 2010, the PBOC announced that the Chinese government would increase the flexibility of the exchange rate, and thereafter allowed the RMB to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC. However, in August 2015, the PBOC significantly devalued the RMB.
The value of our ADSs and our ordinary shares will be affected by the foreign exchange rates between U.S. dollars, HK dollars, and the RMB. For example, to the extent that we need to convert U.S. dollars or HK dollars into RMB for our operations or if any of our arrangements with other parties are denominated in U.S. dollars or HK dollars and need to be converted into RMB, appreciation of the RMB against the U.S. dollar or the HK dollar would have an adverse effect on the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars or HK dollars for the purpose of making payments for dividends on ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar or the HK dollar against the RMB would have a negative effect on the conversion amounts available to us.
Since 1983, the Hong Kong Monetary Authority (“HKMA”) has pegged the HK dollar to the U.S. dollar at the rate of approximately HK$7.80 to US$1.00. However, there is no assurance that the HK dollar will continue to be pegged to the U.S. dollar or that the HK dollar conversion rate will remain at HK$7.80 to US$1.00. If the HK dollar conversion rate against the U.S. dollar changes and the value of the HK dollar depreciates against the U.S. dollar, our assets denominated
in HK dollars will be adversely affected. Additionally, if the HKMA were to repeg the HK dollar to, for example, the RMB rather than the U.S. dollar, or otherwise restrict the conversion of HK dollars into other currencies, then our assets denominated in HK dollars will be adversely affected.
Credit Risk
Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, short-term investments, accounts receivable, and notes receivable.
The carrying amounts of cash and cash equivalents and short-term investments represent the maximum amount of losslosses due to credit risk. As of June 30, 2023March 31, 2024 and December 31, 2022,2023, we had cash and cash equivalents of $859.2$650.8 million and $1,008.5$790.2 million, and short-term investments of $15.5nil and $16.3 million, and nil, respectively. As of June 30, 2023March 31, 2024 and December 31, 2022,2023, all of our cash and cash equivalents and short-term investments were held by major financial institutions located in mainland China and international financial institutions outside of mainland China which we believe are of high credit quality and for which we monitor continued credit worthiness.
Accounts receivable are typically unsecured and are derived from product sales and collaborative arrangements. We manage credit risk related to our accounts receivable through ongoing monitoring of outstanding balances and limiting the amount of credit extended based upon payment history and credit worthiness. Historically, we have collected receivables from customers within the credit terms with no significant credit losses incurred. As of June 30, 2023,March 31, 2024, our two largest customers accounted for approximately 31%21% of our total accounts receivable collectively.
Certain accounts receivable balances are settled in the form of notes receivable. As of June 30, 2023,March 31, 2024, such notes receivable included bank acceptance promissory notes that are non-interest bearing and due within six months. These notes receivable were used to collect the receivables based on an administrative convenience, given these notes are readily convertible to known amounts of cash. In accordance with the sales agreements, whether to use cash or bank acceptance promissory notes to settle the receivables is at our discretion, and this selection does not impact the agreed contractual purchase prices.
Inflation Risk
In recent years, mainland China has not experienced significant inflation. Although the global economy, including the U.S. economy, experienced rising inflation in recent years, which can increase the costs of our products and product candidates purchased from third parties and, as a result, adversely affect our results of operations, inflation has not had a material impact on our results of operations. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected in the future by higher rates of inflation in mainland China or in other countries in which our third-party partners operate.
Item 4. Controls and Procedures
Management’s Evaluation of our Disclosure Controls and Procedures
Our management, including our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rule 13a-15(e)) as of the end of the period covered by this report. Our disclosure controls and procedures are designed to ensure that the information required to be disclosed in the reports that we file or furnish under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective. Based upon that evaluation, our management has concluded that, as of June 30, 2023,March 31, 2024, our disclosure controls and procedures were effective.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as such item is defined in Rules 13a-15(f)) during the fiscal quarter ended June 30, 2023March 31, 2024 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings.
We may be, from time to time, subject to claims and suits arising in the ordinary course of business. We are not currently a party to any material legal or administrative proceedings.
Item 1A. Risk Factors.
We are subject to risks and uncertainties that could, directly or indirectly, adversely affect our business, results of operations, financial condition, liquidity, cash flows, strategies, and/or prospects. There have been no material changes in our risk factors from those disclosed in the “Risk Factors” section of our 20222023 Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
The following table presents acquisitions of the Company’s ADSs from employees by the Company to satisfy tax withholding obligations due in connection with exercise of option shares or vesting of restricted shares during the second quarter of 2023:
| | | | | | | | | | | | | | |
| Period | Total Number of Shares (or Units) Purchased | Average Price Paid per Share (or Unit) | Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs |
| April 1 – 30, 2023 | 2,661 | | $ | 30.70 | | — | — |
| May 1 – 31, 2023 | 914 | | $ | 42.50 | | — | — |
| June 1 – 30, 2023 | 123,658 | | $ | 40.51 | | — | — |
| Total | 127,233 | | | | |
Item 3. Defaults Upon Senior Securities.
None.
Item 4. Mine Safety Disclosures.
None.
Item 5. Other Information.
DuringOther than as described below, during the period covered by this report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K).
On February 23, 2024, William Lis, one of the Company’s directors, adopted a new written Rule 10b5-1 trading arrangement for the disposition of up to 10,397 of the Company’s ADSs, each representing ten of the Company’s ordinary shares, to cover tax obligations in connection with the vesting of a previously granted restricted stock award. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than July 31, 2024.
In addition, in the 2023 Annual Report, the Company inadvertently omitted disclosure regarding the adoption of a new written Rule 10b5-1 trading arrangement on December 13, 2023 by F. Ty Edmondson, the Company’s Chief Legal Officer, for the sale of up to 40,000 ADSs. This Rule 10b5-1 trading arrangement is scheduled to terminate no later than November 29, 2024. In addition, the Rule 10b5-1 trading arrangement adopted by Rafael Amado, the Company’s President, Head of Global Oncology Research and Development, on December 15, 2023 is for the sale of up to 15,750 ADSs, rather than 94,500 ADSs as previously disclosed in our 2023 Annual Report.
Item 6. Exhibits.
Exhibit Index
| | | | | | | | |
Exhibit
Number | | Exhibit Title |
| 10.1# | | |
| 10.2 | | |
| 10.3 | | |
| 10.4 | | |
| 10.5 | | |
| 10.6 | | |
| 10.7 | | |
| 31.1 | | |
| 31.2 | | |
| 32.1 | | |
| 32.2 | | |
| 101.INS* | | Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document |
| 101.SCH* | | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL* | | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.LAB* | | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE* | | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 101.DEF* | | Inline XBRL Taxonomy Extension Definitions Linkbase Document |
| 104* | | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | |
| ZAI LAB LIMITED |
| | |
Dated: August 7, 2023May 8, 2024 | By: | /s/ Yajing Chen |
| Name: | Yajing Chen |
| Title: | Chief Financial Officer |
| | (Principal Financial and Accounting Officer) |
